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CHAPTER 1 
INTRODUCTION 
1.1 Summary 
Senescence is a permanent withdrawal from cell cycle that occurs naturally at a 
cellular level in response to the shortening of telomeres.  This shortening of telomeres is a 
result of the “end replication problem,” which occurs because the ends of the chromosomes 
cannot be effectively replicated.  This natural “clock” serves to limit the number of cell 
divisions and therefore protects the cell from an extended lifespan and potentially 
carcinogenic mutations.  However, senescence also occurs in response to external stresses 
to the cell, which is known as induced senescence.  This study compares the mechanisms 
of natural senescence, a response to the shortening of telomeres during replication, with 
induced senescence by using a variety of drugs to induce senescence: 5-aza-2-
deoxycytidine (a DNA demethylating agent), adriamycin (a chemotherapeutic drug), and 
H2O2 (an agent causing oxidative stress). 
MDAH041 cells, which are fibroblasts isolated from a patient with Li Fraumeni 
Syndrome, have heterozygous alleles of p53 (one wild-type allele and one allele with a 
frameshift mutation causing a protein truncation).  Fibroblasts from LFS patients can either 
undergo natural senescence with serial cell culture because of the wildtype, functional p53  
or at a low frequency spontaneously immortalize once the wild-type copy of p53 is lost.  
Therefore, this cell model provides naturally senescent cells as well as immortal cells 
which can be treated with the aforementioned drugs resulting in induced senescence.  Using 
these conditions, gene expression profiling was performed.  Gene expression analysis 
revealed 48 genes differentially expressed specifically in all 4 senescence types compared 
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to the immortal control.  Pathway analysis of these 48 genes from these 4 types of cellular 
senescence revealed several pathways, which are all  involved in innate immunity, showing 
for the first time a common gene expression profile among different types of senescence, 
as well as a central role for the IFN pathway in both natural and induced senescence.  
Specifically, the IL1 pathway was found to be up-regulated in all 4 types of senescence 
compared to immortal proliferating cells.  
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1.2 Multistep Carcinogenesis 
The development of cancer has long been considered to be a multistep mechanism, 
consisting of more than just one determining factor.  Vogelstein’s model of multistep 
carcinogenesis involved an average of 3 to 6 mutations during malignancy, either the loss 
of tumor suppressor genes or the activation of oncogenes [1].  Preceding Vogelstein, Farber 
described stepwise progression of cancer consisting of an initiation step, promotion and 
progression [2].  Initiation was shown to involve some mutagenic change in DNA, due to 
chemical interactions, radiation or other carcinogens.  After initiation, promotion occurs, 
resulting in an expanded population of cells resembling the original initiated cell.  Finally, 
progression results in a malignant transformation of cells which yields cancer [2].   
Several studies showed that oncogenes alone could not transform normal cells.  One 
example of this was the addition of an EJ oncogene (a mutant form of the human H-ras) to 
a normal hamster fibroblast line, which did not cause transformation.  However, if this 
oncogene was added to the fibroblasts after being immortalized, malignant transformation 
was observed indicating several steps in the pathway to tumorigenesis [3].  Similarly, 
embryonic cells transfected with the Ras oncogene did not become transformed unless the 
cells were immortalized previously.  If the Ras oncogene was introduced in conjunction 
with a Myc oncogene or the SV40 virus large T antigen, transformation did occur and the 
embryonic cells became malignant [4].  Therefore, tumorigenesis is multistep mechanism 
and is not the result of single genetic changes. 
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1.3 Cellular Senescence 
In 1961, Leonard Hayflick observed the cellular changes that are now collectively 
known as cellular senescence [5].  Hayflick initially described the tendency for fibroblasts 
to replicate only a limited number of times, and then enter a growth arrest or replicative 
senescence after approximately 60-80 cell doublings [5].  This was later found to be due to 
the “end replication problem” resulting from inefficient replication of the chromosome 
ends during replication [8].  In addition to spontaneous senescence, cells can be induced to 
undergo senescence in response to a variety of stimuli such as DNA damage (as with 
chemotherapeutic agents like adriamycin), oncogenic/mitogenic signals (as with H-Ras 
activation in the cell and termed specifically oncogene-induced senescence or OIS) and 
cellular stress (such as the oxidative stress following H2O2 treatment) [5].  Cellular 
senescence represents a checkpoint applied to the cell cycle that prevents cells from 
accumulating mutations that could enable them to develop an indefinite lifespan or 
“immortality”, a step on the pathway to tumorigenesis.   
The cells used in this thesis research are from patients with Li Fraumeni Syndrome, 
and provide a good example of the multistep nature of carcinogenesis.  The cells contain 
heterozygous copies of p53 (one wild-type allele and one allele with a mutation), and 
therefore become immortalized upon the loss of the wild-type copy of p53. However, the 
loss of p53 was found to be necessary but not sufficient to cause immortalization, again 
indicating multiple steps in cancer development [6].  Additionally, these immortal cells are 
not yet transformed and require even further mutations to yield a cancerous phenotype.  
These mutations may be due to the genomic instability caused by p53 insufficiency.  Upon 
transfection of a Ras-oncogene these immortal cells can become tumorigenic [7].   
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Telomere shortening leads to spontaneously senescent cells with a finite number of 
population doublings.  The repetitive DNA segments at the ends of the chromosomes 
average approximately 12 kb in human cells, but a limited number cannot be synthesized 
at each round of replication, due to the “end replication problem.” Therefore telomeres 
become shorter with age [8].  When the telomeres become too short, a DNA damage 
response is triggered through the activation of p53 and pRb [8].  Immortal cells must be 
able to overcome the shortening of telomeres in order to replicate indefinitely.  The 
majority of cancers do this by expressing an enzyme called telomerase which adds the 
repetitive DNA sequences on to the ends of chromosomes so that the telomeres never 
become so short that they trigger a DNA damage response [9].  A less common method for 
cancer cells to maintain their telomere length is known as alternative lengthening of 
telomeres, or ALT.  This mechanism employs homologous recombination to ensure the 
telomeres do not become too short and occurs in only 10-15% of cancers [10].  
Appropriately, gene expression changes between young cells and naturally senescent cells 
are decreased when hTERT is expressed in the cells, indicating that most gene expression 
changes are indeed due to telomere shortening [11].  It is important to note for this study 
that human fibroblasts that contain telomerase and are immortal can still be induced to 
senescence with various chemical agents that induce DNA damage independent of the 
telomeric DNA shortening [12]. 
In addition to the bypass of senescence through activation of telomerase or ALT, it can 
also be bypassed by inactivation of tumor suppressors.  For example, viral oncoproteins 
can bind and inactivate tumor suppressor genes.  SV40 (simian virus 40) large T antigen 
can bind and inactivate the p53 and pRb tumor suppressors which causes a bypass in the 
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senescent response [13, 14].  The E6 protein of the human papilloma virus can bind and 
inactivate p53 which also yields a bypass of the senescent response [15].  Additionally, the 
oncoprotein E7 from the human papilloma virus can complex with and inactivate pRb [16, 
17]. 
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1.4 Known Senescence Genes  
The two main mechanisms associated with cellular senescence involve the p53 and Rb 
pathways mentioned previously.  Both proteins serve as tumor suppressors and protect the 
cell from acquiring genetic mutations or DNA damage by activating a cell cycle 
checkpoint, which prevents a cell from becoming malignant.  In the event of telomere 
attrition, cytotoxic drugs, and oncogene introduction, ATM/ATR or CHK1/2 genes 
become activated, which leads to the accumulation of p53.  Additionally, p53 can be 
activated by p14ARF, which binds to MDM2 (a ubiquitin ligase) and therefore prevents 
the degradation of p53 [18].  The accumulation of p53 leads to the subsequent 
transcriptional activation of cell cycle inhibitor p21cip1, and the activation of cellular 
senescence through the inhibition of cyclin/CDK complexes.   
Alternatively, the Rb/p16 pathway can also lead to cellular senescence.  p16INK4a has 
been shown to be up-regulated in stressed and senescent cells, thus inhibiting cyclin D and 
cyclin-dependent kinases.  This prevents the phosphorylation of Rb, which leaves Rb 
available to bind E2F family members.  The subsequent association of Rb and E2F renders 
E2F unable to bind target genes and activate them during S-phase of the cell cycle [18].  
Therefore, up-regulation of p16 ultimately leads to transcriptional repression of cell cycle 
genes through E2F.  This prevents the progression through cell cycle and leads to a 
phenomenon known as Senescence Associated Heterochromatic Foci, or SAHF, which is 
a condensed chromatin structure that further prevents E2F activity on target gene promoters 
[19, 20].  However, it has also shown that formation of SAHF may be cell-type and 
damage-type specific [20].  Rb1 is a member of the pocket protein family, consisting of 
two additional members p107 and p130, however inactivation of these two family members 
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are rarely observed in cancer and there is little evidence to show a role for them during 
senescence [18].  The INK4A-ARF locus which encodes both the p16 and p14 proteins is 
the most commonly mutated or deleted locus in human tumors, allowing the cell to bypass 
senescence by p53 and Rb simultaneously [18]. 
Whether senescence is induced by activation of p53 or p16, it is dependent on the type 
of stress inflicted upon the cell.  However, in many cases, expression of both p53 and p16 
remain after sustained senescence.  For example, a senescence induced by the p53 response 
to DNA damage can also exhibit p16 activation after prolonged senescence due to p38-
MAPK pathway activation and ROS production [21]. 
In addition to the tumor suppressor genes that are frequently altered in expression after 
senescence, there are many other genes that play a role in senescence, including genes that 
were identified in the Tainsky laboratory [22].  RNA expression was analyzed during 
senescence using fibroblasts from a patient with Li Fraumeni Syndrome, which is a 
heritable cancer syndrome caused by a germline mutation in one allele of p53 [23].  The 
heterozygous mutation in p53 creates a unique cellular model system in that the fibroblasts 
can either enter senescence with telomere attrition (because of the wild-type allele of p53), 
or can undergo loss of the wild-type copy of p53 which leads to spontaneous 
immortalization.  This characteristic is not observed in any other genetic syndrome [24].  
These cells were previously used in our lab to study immortalization and senescence 
induced by treatment with 5-aza-2’-deoxycytidine, showing that 5-aza reverses epigenetic 
silencing of genes during immortalization.  That study used Affymetrix microarray analysis 
to identify genes with altered expression in senescence.  By comparing immortal LFS 
fibroblasts with senescent LFS fibroblasts induced into senescence by treatment with 5-
9 
 
 
 
aza, it was found that there are 3 critical pathways involved in cellular immortalization: 
cytoskeleton, cell cycle and interferon pathways [22].  Cytoskeletal changes were not 
surprising, given the large flattened morphology of fibroblasts during senescence.  Cell 
cycle gene expression changes were also not surprising, because the cells must withdraw 
from the cell cycle in order to cease division and enter senescence.  However, the interferon 
pathway’s involvement in senescence was an unexpected finding of the study.  
Additionally, senescent-associated genes were identified by identifying the unique subset 
of genes that were both up-regulated in senescence and down-regulated in immortalization, 
in all 4 of the LFS cell lines used.  This approach also identified a list of 14 genes that met 
these criteria: ALDH1A3, CLTB, CREG, CYP1B1, FLJ14675, HPS5, HSPA2, HTATIP2, 
IGFBPrP1, KIAA1750, MAP1LC3B, OPTN, SERPINB2 and TNFAIP2 [22].  When 
identifying possible senescence genes, one strategy is to look at genes that are up-regulated 
in senescence and down-regulated in immortalization because senescence has been shown 
to be a dominant pathway [25].  
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1.5 Senescence as a Tumor Suppressive Mechanism 
Senescence provides a barrier to tumor progression both in vitro and in vivo,  as 
evidenced through several studies, including a study of the E2F3 transcription factor, in 
which E2F3 was ectopically expressed in the pituitary gland, leading to hyperplasia, but 
subsequently led to induction of senescence [26].  Additional studies include the discovery 
of senescent cells in benign naevi (moles) which typically exhibit BRAF oncogenic 
mutations and a study in which RasV12 was conditionally expressed in a mouse lung, 
leading to pre-neoplastic lung adenomas but rarely progressed to neoplastic adenomas [18, 
27].  Senescence in the presence of an oncogene is termed oncogene-induced senescence 
or OIS.  The role of senescence in preventing progression of pre-neoplastic lesions to 
malignant cancer has been shown in cancers of the prostate, colon, lymph and breast [18].   
Benign melanocytic nevi in vivo were found to contain BRAF mutations, concurrent with 
positive staining for senescence-induced -galactosidase staining [28].  This would 
indicate that when a cell obtains an oncogene, a form of senescence is activated to prevent 
proliferation of that cell.  Additionally, markers of senescence have been found in vivo in 
several types of early neoplastic tissues, such as lung adenoma, mammary tumors, 
lymphomas, liver carcinomas and prostate neoplasias [29]. Therefore, evidence indicates 
that senescence is a barrier to tumorigenesis.  The senescence that occurs as a result of 
activation of an oncogene such as Ras or BRAF is a known natural cellular mechanism of 
carcinogenesis suppression.  It is thought that the increased replication due to oncogenic 
activation causes an abundance of DNA damage and consequently a DNA damage 
response via the p53 and pRb pathways [30].  It has also been proposed that the DNA 
damage response can be triggered by increased levels of ROS, which is a consequence of 
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oncogenic Ras expression [31].  Oncogene-induced senescence is a recently-identified 
mode of tumor suppression, similar to the classic tumor suppression mechanism of cell 
cycle arrest.  However, oncogene-induced senescence is thought to be irreversible, whereas 
generic cell cycle arrest (quiescence) due to DNA damage can be reversed if the DNA 
damage is repaired and the cell is allowed to re-enter the cell cycle [32].  In addition to 
oncogene-induced senescence and cell cycle arrest, tumor suppression largely occurs via 
apoptosis when damage to the cell is too extreme to repair [32].  The tumor suppressor p53 
dictates whether a cell will undergo senescence, quiescence or apoptosis in response to 
DNA damage [33].  Under normal conditions, p53 has a low level of expression, which is 
maintained through MDM2, an E3 ubiquitin ligase that ubiquitinates p53 and targets it for 
degradation [33].   
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1.6 Senescence Markers  
Markers of senescence include prolonged withdrawal from cell cycle, enlarged 
morphology, senescence-associated -galactosidase staining, increased levels of p16 and 
p21 and the formation of senescence-associated heterochromatic foci (SAHF) as well as a 
senescence-associated secretory phenotype (SASP).  Senescence-associated -
galactosidase staining is an assay that results from the accumulation of -galactosides 
within the lysosome of senescent cells due to enlarged lysosomal mass [34].  Because of 
this, -galactosidase is able to catalyze the hydrolysis of -galactosides into 
monosaccharides, which then results in the cleavage of 5-bromo-4-chloro-3-indolyl--D-
galacto-pyranoside (X-gal), which leads to a blue precipitate at pH 6.0 [35].  Another 
indicator of senescence is the decrease in expression of cell-cycle and proliferation related 
genes, such as cyclin A and cyclin B, though these reductions in expression are not specific 
to senescence but rather the withdrawal of the cell from the cell cycle  [36].  Additionally, 
the increase in expression of cyclin-dependent kinase inhibitors such as p21 can also 
indicate senescence [37]. 
SAHF or senescence-associated heterochromatic foci are areas of transcriptionally 
silent and compacted chromatin that result from the presence of repressive histone mark 
H3K9me3 and absence of activating histone mark H3K4me3 [38].  It is probable that 
SAHF maintains the cell in a non-proliferating state, as the E2F transcription factors cannot 
bind to the compressed and therefore inaccessible chromatin, which prevents  transcription 
of S-phase cell cycle related genes [19].  The occurrence of SAHF is dependent upon the 
cell type, as well as type of damage inflicted, but seems to be consistently associated with 
the activation of the tumor suppressor p16 [20].  In oncogene-induced senescence, the 
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formation of SAHF occurs concurrently with DNA damage response and also correlates to 
the increased expression of p16 [39]. 
The senescence-associated secretory phenotype is a collection of factors that are 
secreted from senescent cells [40].  The factors are considered to be inflammatory, 
including members from the IL1 family, proteases, MMPs and chemokines, several of 
which were identified in our RNA-seq to be up-regulated in senescence [41].  The effect 
of the SASP is controversial, with evidence for these factors causing paracrine senescence 
to surrounding cells or causing chronic inflammation and therefore contributing to 
malignant phenotypes [41].  Secreted factors are also thought to attract immune factors to 
aid in the elimination of senescent cells [42]. 
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1.7 Senescence Induction 
Senescence can be induced by a variety of mechanisms.  Firstly, oncogene-induced 
senescence can be achieved through the expression of an oncogene such as a mutated Ras 
[39].  Secondly, there are several chemical agents that can induce senescence through DNA 
damage or other stresses, such as chemotherapeutic agents and DNA damaging agents [43].  
Thirdly, senescence can be induced through the re-activation of tumor suppressive 
pathways such as p53 or p16 by re-introducing these genes back into cells or reversing 
their silencing through epigenetic remodeling [44].  Lastly, genes that are up-regulated 
during senescence such as IRF5 and IRF7 can be ectopically expressed in cells to cause 
senescence [45].  This project utilizes hydrogen peroxide, adriamycin and 5-aza-2-
deoxycytidine to induce senescence. 
H2O2 (hydrogen peroxide) has been shown to induce senescence in various cell types 
at sublethal concentrations [46].  At high concentrations, H2O2 treatment can result in 
apoptosis.  H2O2-treated cells were shown to be arrested in G1, which reflects senescent 
arrest [46].  p53 is temporarily up-regulated in these cells, while p21 showed a long-term 
up-regulation in response to H2O2 exposure [46].  Rb maintains low levels of 
phosphorylation, which is consistent with the senescent response: when Rb is not 
phosphorylated, it binds E2F and prevents transcription of proliferation-related genes [46].  
H2O2 treated cells have been found to be senescent-associated -galactosidase positive and 
have irreversible growth arrest [47]. 
5-aza-2-deoxycytidine is a DNA methyltransferase inhibitor that results in 
demethylation of promoters within the genome.  5-aza is a cytosine analog that incorporates 
into DNA, and covalently traps DNMTs, preventing further methylation activity [48].  
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Because many CpG islands in tumor suppressive promoters are frequently hyper-
methylated in cancers, the demethylating action of 5-aza-2-deoxycytidine causes 
senescence through reactivation of tumor suppressors epigenetically silenced during 
immortalization, such as p16 [49].   5-aza treatment of immortal LFS cells (the same type 
of cells used in this study) has shown three pathways affected by treatment: cytoskeletal 
pathway, cell cycle pathway, and the interferon pathway [22].  Further study has shown 
the loss of expression of the interferon pathway in immortalization of these cells, which 
can be thought of as the inverse of senescence [22].  High levels of histone 3 lysine 9 
(H3K9) methylation have been shown in heterochromatin silenced genes, but this effect is 
reversed in response to treatment with 5-aza, indicating a possible role of 5-aza in histone 
demethylation [50].  An additional study showed that treatment of cells with 5-azacytidine 
(a DNMT inhibitor that incorporates into both the DNA and RNA) caused changes in 
histone modification patterns [51]. 
Adriamycin is an anthracycline antibiotic that is frequently used in the treatment of 
breast cancer.  This drug typically causes induction of apoptosis when used chronically, 
however short-term acute treatment favors the senescent pathway [52].  Treatment with 
adriamycin has been shown to cause an increase in p53 levels, and decrease in telomerase 
levels, though the mechanism of action seems to be telomere length independent [52]. 
  
16 
 
 
 
1.8 Senescence and Aging 
Aging at a cellular level occurs through the shortening of telomeres, which limits 
the number of times a cell can proliferate.  When the telomeres become critically short, a 
DNA damage response is triggered and the cell enters senescence rendering it unable to 
replicate [53].  As an organism ages, telomere length of cells is known to decrease overall, 
and the number of senescent cells with critically short telomeres is known to increase [53].  
Additionally, syndromes of premature aging exhibit shortened telomeres compared to 
normal cells of these patients [53].  Several aging-related diseases such as infertility and 
digestive tract atrophies have also been shown to have shortened telomeres [53].  
Telomerase-deficient mice showed early aging but a higher resistance to cancer, and 
telomerase-null mice showed a decline in longevity [54]. 
Aging at an organismal level is a risk factor for a myriad of disorders, including 
stroke, heart disease, cancer, dementia, osteoporosis, kidney failure, blindness and arthritis 
[55].  Many of these disorders are a direct result of chronic inflammation, which has 
recently been found to be in part due to the senescence-associated secretory phenotype 
[55].  It has also been proposed that the elimination of senescent cells may reduce chronic 
inflammation and therefore decrease the amount of chronic disease due to aging [55].  Early 
hypotheses about senescence’s role in aging came from knowledge that tumor suppressors 
such as p53 and p16, which are up-regulated during senescence, cause mortality due to 
cancer at a young age when ablated in mice.  However, until recently it was difficult to 
prove the involvement of senescent cells in the aging phenotype due to lack of in vivo 
markers for senescence.  The most common markers for in vivo detection of senescence 
are senescence-associated -galactosidase and elevated levels of p16; however p21, 
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macroH2A (a histone variant), IL-6 and DNA damage can also be observed [21]. Using 
these markers, senescent cells have been shown in age-related diseases such as 
osteoarthritis, pulmonary fibrosis and Alzheimer’s disease [21]. 
 Further evidence for senescence in aging comes from a study of selective p16 
elimination from a mouse model.  Using a transgene INK-ATTAC (which targets p16 for 
destruction through caspase activation), cells showing a high level of p16 (senescent cells) 
were selected for apoptosis.  This selective elimination of p16 halted the progression of 
aging disorders in skeletal muscle and fat [56].  The role senescent cells play in tissue 
degeneration and organ dysfunction is unknown.  It is possible that degeneration and 
dysfunction are caused by a simple decrease in tissue regenerative potential, but several 
things are thought to contribute to this phenotype.  The microenvironment of aged cells 
limits stem cell viability, and regenerative potential of stem cells is improved when 
introduced to a “young” cell microenvironment [21].  Similarly, senescent cells secrete 
proteases that can disrupt tissues and membrane-bound receptors, as well as other 
components of the environment [21].  Other secreted factors such as IL6 and IL8 can 
stimulate tissue fibrosis.  As a whole, the senescence-associated secretory phenotype can 
cause chronic inflammation which is associated with aging and the consequent 
development of age-related diseases [21].  These inflammatory factors can “spread” 
senescence to surrounding cells which exacerbates the senescent phenotype and tissue 
degeneration, but these factors can also promote survival and proliferation, which is 
consistent with the notion that cancer drastically increases in old age [21].  This may 
explain why the production of senescent cells increases with time, or it is also possible that 
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the elimination of senescent cells simply decreases with time which would cause an 
accumulation of senescent cells.  
1.9 Antagonistic Pleiotropy 
Antagonistic pleiotropy as it pertains to senescence was introduced in 1957 by 
George Williams.  Briefly, antagonistic pleiotropy describes a phenomenon in which 
organisms can evolve mechanisms that hinder their overall survival but they are beneficial 
early in life [57].  Williams asserted that natural selection will promote genes beneficial 
during youth at the expense of adult life, because “an advantage during the period of 
maximum reproductive probability would increase the total reproductive probability more 
than a proportionately similar disadvantage later on would decrease it” [57].  Senescence 
fits this definition of antagonistic pleiotropy because it is beneficial early in life, serving to 
limit cancers but as an organism ages senescence will cause frailty, decreased regenerative 
capability and a general “old age” phenotype.   
 There is some evidence against senescence as antagonistic pleiotropy.  Although 
the senescence-associated secretory phenotype is generally thought to have a negative 
effect because the secreted factors can promote cancer, some believe that the secreted 
factors are beneficial as they promote clearance by the immune system [58].  Senescence 
also plays a role in wound healing and tissue repair, which can prevent organ degeneration 
and tissue fibrosis and is therefore beneficial in late life [58].   It has also been noted that 
there is no definitive evidence that cites senescence as being more beneficial in young life 
compared to late life, or conversely that the detriments of senescent are more prevalent in 
late life than young life [58]. 
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1.10 Senescence and the Interferon Pathway 
Previous analysis of senescence pathways was performed in the Tainsky laboratory 
through gene expression studies of immortal LFS cells, proliferating versus those induced 
into senescence by 5-aza-2’-deoxycytidine.  Three main pathways were found to be altered 
in immortalization and senescence: cell cycle, cytoskeleton and the interferon pathway 
[22].  Cell cycle was expected to be altered, due to a senescent cell’s halt in growth and 
associated withdrawal from cell cycle.  Cytoskeletal alterations are also not surprising 
given the stretched and enlarged morphology of a senescent cell.  Therefore, the surprising 
finding was that of the interferon pathway, and this was studied extensively.   
The Tainsky laboratory previously identified several interferon genes epigenetically 
silenced during immortalization [22, 48]; these genes were also found to be up-regulated 
in both natural senescence and senescence induced by 5-aza-2’-deoxycytidine [49].  
Further confirmation of these genes showed that overexpression of interferon regulatory 
factors IRF5 and IRF7 was able to inhibit growth and induce senescence in immortal LFS 
cells [45].  However, it was also shown that STAT1 expression was not sufficient to 
regulate this senescent interferon response [25].  Immortal cells with abrogated interferon 
signaling had a higher tolerance to miRNA created by overexpression of DICER, while 
cells with a normal interferon response responded to overabundance of miRNA with cell 
death, inhibition of growth and senescence.  This indicates a role for abrogation of the 
interferon pathway in early immortalization [59].  Because these changes were shown only 
in 5-aza-induced senescence, which is essentially the reversal of immortalization-related 
epigenetic silencing through the removal of methylation marks, the current study focused 
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on other types of induced senescence to assess whether the interferon pathway played a 
role in other types of senescence with different mechanisms of induction.   
Other laboratories have reported a role for the interferon pathway in cellular 
senescence.  Senescence induced by 5-bromo-2’-deoxyuridine, distamycin, aphidicolin or 
hyrdoxyurea in both normal and cancer cells were found to activate JAK/STAT signaling, 
expression of interferon-stimulated genes such as the IRFs (interferon regulatory factors), 
as well as several interleukins and interferons [60].  Knockdown of JAK1 in this study was 
found to abrogate the expression of interferon-stimulated genes [60]. It has been shown 
that interferon cytokines are inhibitors of cell growth, both in vivo and in vitro, which is 
consistent with the idea that they are involved with senescence [61].  cDNA microarray 
analyses showed the interferon pathway to be silenced in a model of human prostate cancer, 
and up-regulated in senescent human prostate epithelial cells [62].  Analysis of prostate 
cancer cells via serial analysis of gene expression (SAGE) showed up-regulation of 
interferon genes [63].  The specific role of interferon genes in cellular senescence and 
immortalization is largely unknown, however a small number of specific interferon genes 
have been characterized, such as Choubey et al. who identified IFI16 as a key regulator of 
senescence in prostate epithelial cells [64].  Another example is IFN- which has an anti-
proliferative effect on gastric cancer cells [65] and can induce senescence in normal 
melanocytes [66]. 
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1.11 The Interleukin 1 Pathway and Senescence 
The senescence associated secretory phenotype is known to include members of the 
Interleukin 1 (IL-1) pathway [41].  IL1- or IL1-bind to the IL1 receptor (IL1R) and 
cause interaction with Myd88, an adaptor protein [67].  Activation of this adapter then 
causes downstream activation of IRAKs (interleukin-1 receptor associated kinases) and 
consequent activation of NF-kB [67].  The activation of NF-kB is thought to trigger the 
release of inflammatory cytokines that comprise the senescence associated secretory 
phenotype, including IL1-, IL1-, IL-8 and ICAM1 among several others.  IL1- is 
mainly membrane-bound, while IL1- is mainly secreted when activated [68].  
IL1- was found to be necessary for the secretion of downstream inflammatory factors 
during senescence, such as IL-6 and IL-8 [68].  During senescence, fibroblasts were found 
to have high amounts of membrane-bound IL1-, intracellular IL1- and IL1- mRNA, 
however very little secreted IL1- [68].  Neutralizing IL1- levels through IL1- 
antibodies, IL1- RNA interference and an IL1R antagonist all caused a decrease in 
senescence-associated IL-6 and IL-8 secretion, however the effect on amount of 
senescence was not noted in that study [68].  This study also showed a decrease in paracrine 
effects of the inflammatory phenotype: conditioned media from senescent cells depleted in 
IL1- did not have as much of an invasive phenotype in metastatic cancer cells [68].  
Conditioned media from cells undergoing replicative senescence, oncogene-induced 
senescence or drug-induced senescence contains high levels of Il-1, IL-6 and TGF, which 
can cause increased DNA damage by ROS [69].  This media is able to induce DNA damage 
and senescence in bystander cells [69].  Briefly, young BJ fibroblasts were exposed to 
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senescence-conditioned media from BJ fibroblasts undergoing oncogene-induced 
senescence, replicative senescence, or drug-induced senescence.  The young BJ cells 
exhibited increased levels of H2AX (a marker for DNA damage) as well as increased 
levels of senescence-associated -galactosidase staining indicating senescence [69].  
Additionally, U2OS osteosarcoma cells with a stably expressed GFP tag were mixed with 
U2OS cells that had undergone drug-induced senescence, and the GFP-positive cells 
showed an increase in H2AX DNA damage foci [69].  Similarly, independent studies 
showed that oncogene-induced senescence activates a senescence-associated secretory 
phenotype and media from these cells can cause paracrine senescence through the IL-1 
signaling network [70].  However, this study found that while IL1- alone can induce a 
senescence-associated secretory phenotype when up-regulated, neutralization of both IL1-
 and Il1- through antibodies or through the knockdown of the IL1R was necessary to 
block the senescence-associated secretory phenotype [70].  The increase in IL-1 is due to 
senescence-associated changes in steady-state H2O2 levels, and therefore intracellular Ca
2+ 
levels which promote calpain activation and causes cleavage to mature IL1- [71]. 
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1.12 Senescence and Cancer Therapy 
The controversy surrounding senescence’s usefulness during cancer therapy greatly 
increased with the discovery of the senescence-associated secretory phenotype.  
Senescence was initially thought to be a beneficial outcome of cancer therapy, rendering 
the cells unable to replicate and therefore prevent tumor growth.  However, it has also been 
shown that senescent cells secrete inflammatory factors that can lead to chronic 
inflammation and consequently tumorigenesis [40].  Another theory is that senescence 
improves cancer therapy, but the senescent cells need to be expediently removed to avoid 
negative consequences of senescence [72].  Other approaches include preventing 
senescence altogether, or targeting the SASP to eliminate negative repercussions of 
lingering senescent cells [55].  Chronic inflammation as a result of normal aging is the 
leading cause of dementias, depression, atherosclerosis, cancers, diabetes and mortality 
[55].  This chronic inflammation may be due to an accumulation of senescent cells as the 
body ages.  
It is has been shown that senescent cells can be removed through the targeting of the 
biomarker p16.  In a study with BubR1 progeroid mice as a model, a transgene INK-
ATTAC was administered, and upon addition of a drug, the p16-positive cells, which are 
considered senescent, were removed through apoptosis.  When the p16-positive cells were 
removed throughout the mouse’s entire lifespan, age-related pathologies were prevented in 
tissues such as adipose, skeletal muscle and eye, where p16 expression is generally 
increased with age.  Additionally, when the p16-positive cells were cleared in late-life 
mice, the age-related disorders halted progression [56].  That study not only indicates a 
causal role for senescence in aging-related pathologies, but provides a proof of principle 
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that it may be possible to eliminate senescent cells in vivo, which will be significant in both 
cancer therapy and aging prevention. 
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CHAPTER 2 
METHODS 
2.1 Cell Culture and Cell Lines 
Li-Fraumeni Syndrome (LFS) is an inherited cancer syndrome caused by germline 
mutations in the tumor suppressor p53.  Patients with this syndrome are prone to several 
types of cancers, including breast cancers, soft tissue sarcomas, brain tumors, 
osteosarcomas, leukemias, lymphomas and adrenocortical carcinoma [73].  Dermal 
fibroblasts from these patients were established in cell culture, and characterized [74].  It 
was found that though these fibroblasts can grow normally and senesce due to telomere 
erosion as a normal cell would, they could also lose their functional copy of p53 due to 
genomic instability and spontaneously immortalize [7].  The immortal cells obtained 
included MDAH041, MDAH172, MDAH174 as well as four independent 
immortalizations of the same cell line: MDAH087-N, MDAH087, MDAH087-1 and 
MDAH087-10.  These immortal cells show altered morphology, as well as chromosomal 
anomalies and can be transformed by oncogenes to form tumors [7].  It is important to note 
that fibroblasts from normal patients or other cancer predisposing syndromes do not 
spontaneously immortalize in culture.  MDAH041 early passage cells possess one allele 
with a frameshift mutation at amino acid 184 of p53, which results in a truncated p53 
protein with no function.  Spontaneously immortalized MDAH041 cells subsequently lose 
their wild-type copy of p53 and therefore have no copies of functional p53 [74].  
MDAH041 cells contain active telomerase and therefore maintain short but stable telomere 
lengths.  MDAH172 and MDAH174 cells have a missense mutation at codon 175 of p53, 
and the MDAH087 cells have a missense mutation at codon 248 of p53 [74].  MDAH172, 
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MDAH174 and MDAH087 immortal cells do not have active telomerase but maintain long 
telomeres through the alternative lengthening of telomeres (ALT) mechanism [74, 75]. 
MDAH041 cells were derived from primary fibroblasts by skin biopsy from an LFS 
patient and were spontaneously immortalized in vitro.  Immortalized LFS MDAH041 
fibroblasts, as well as the 3 other LFS cell lines: MDAH087-1, MDAH087-N and 
MDAH172 were grown in Modified Eagles Medium (MEM, Invitrogen). Cells were 
supplemented with 10% fetal bovine serum (FBS, Hyclone), 100 units/ml penicillin and 
100 µg/ml streptomycin (Invitrogen) and were maintained at 37oC in 5% humidified CO2.  
Cells were maintained through passage from 1 plate to 4 plates every 3 days. 
2.2  Senescence-Inducing Drug Treatments 
H2O2 treatment was performed by plating immortal LFS cells at 4x10
5 cells per 10 
cm plate and adding H2O2 to cell media at a final concentration of 20 µM for MDAH-087-
N and MDAH087-1, 25 µM for MDAH172 and 85 µM for MDAH041 cells and incubating 
at 37oC for two hours in 5% CO2.  Optimal concentration of H2O2 for each cell line was 
determined by greatest number of SA--galactosidase positive cells.  Plates were then 
washed with PBS and replenished with growth media, and incubated at 37oC for 5 days. 
5-aza-2-Deoxycytidine treatment was performed by plating immortal LFS cells at 
3x105 cells per 10 cm plate, adding fresh preparations of sterile 5-aza in 50% acetic acid to 
cell media to a final concentration of 1 µM every other day and plates were harvested on 
day 8. 
Adriamycin treatment was performed by plating immortal LFS cells at 4x105 and 
adding a stock of adriamycin dissolved in water to cell media at a final concentration of 
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0.50 µM for MDAH041 cells and 0.20 µM for MDAH087-1, 087-N and 172 cells.  Optimal 
concentration of Adriamycin for each cell line was determined by greatest number of SA-
-galactosidase positive cells.  Cells were treated for two hours (MDAH041) or 1.5 hours 
(087-N, 087-1 and 172) at 37 oC, were washed with PBS and growth media was 
replenished.  Cells were grown at 37oC for 5 days before harvest.   
Proliferating cells were harvested at a lowest population doubling (PD 10-12), low 
population doubling (PD 18-20) and one plate of proliferating cells was kept to expand for 
naturally senescent cells of the same line.  Naturally senescent cells were achieved through 
serial passaging at a 1 to 2 split until cells halted proliferation and appeared 
morphologically senescent (PD 29-30). Immortal cells were employed at high population 
doublings (greater than 200).  Quiescent cells were obtained by plating immortal cells at 
3x105 cells per 10 cm plate, washing the next day with PBS, and adding media with 0.1% 
serum.  Cells were then incubated for 24 hours and harvested. 
2.3 Real-Time PCR and Primers 
cDNA was prepared from 3 µg of RNA, using the Superscript II system from 
Invitrogen.  Q-RT-PCR was performed using Power SYBR Green MasterMix from 
Applied Biosystems and analyzed on the ABI 5700 Sequence Detection System (Applied 
Biosystems).  Primers for each gene analyzed are listed in Table One.  The relative fold 
change was calculated using the CT method as follows: 2
-ΔΔCT, where, ΔΔCT = (CT Gene of 
interest - CT GAPDH) experiment - (CT Gene of interest - CT GAPDH) control.  Statistical significance was 
determined through student’s t-test and a p-value of less than 0.05 was considered 
significant.   
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 Table 1: Primers used for RT-PCR 
  
IL1A Forward CTTAAGCTGCCAGCCAGAGA
IL1A Reverse ACCAAACCAGGGAGGGACAA
IL1B Forward CCAGCTACGAATCTCCGACC
IL1B Reverse CATGGCCACAACAACTGACG
Myd88 Forward CCTCAAGTCCTGGGGAAATGC
Myd88 Reverse AAGGCTCAGGAGACCCACTG
IL8 Forward GAGACAGCAGAGCACACAAG
IL8 Reverse GATGTGCTTACCTTCACACAGA
ICAM1 Forward GGTAGCAGCCGCAGTCATAA
ICAM1 Reverse TCCCTTTTTGGGCCTGTTGT
IRF5 Forward TTCTCTCCTGGGCTGTCTCTG
IRF5 Reverse CTATACAGCTAGGCCCCAGGG
IRF7 Forward GCAGCGTGAGGGTGTGTCTT
IRF7 Reverse GCTCCATAAGGAAGCACTCGAT
Cyclin A2 Forward AGTGATGTTGGGCAACTCTG 
Cyclin A2 Reverse TCCGGGTTGATATTCTCCTG
GAPDH Forward ATCAAGAAGGTGGTGAAGCAG
GAPDH Reverse TGTCGCTGTTGAAGTCAGAGG
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2.4 RNA Extraction  
RNA was extracted from 10 cm plates of 80% confluent cells of all conditions using 
the QIAGEN RNeasy Kit (QIAGEN).  Fully supplemented media was added to the cells 
approximately 18 hours before harvest to ensure cell cycle participation. 
2.5 Immunocytochemistry and Antibodies  
 Cells were plated in 2-well chamber slides (Thermo-Scientific).  Cells were fixed 
with 4% paraformaldehyde for 15 minutes at room temperature, washed three times with 
PBS and permeabilized with 0.1% Triton for 15 minutes.  Slides were then washed three 
times with PBS and blocked with 0.2% BSA for 30 minutes and incubated with primary 
antibody suspended in 0.2% BSA for 1 hour at room temperature.  Following three PBS 
washes, slides were incubated with appropriate secondary antibodies suspended in 0.2% 
BSA for one hour at room temperature.  Three washes with PBS were performed and excess 
PBS was allowed to evaporate from the chamber before Prolong Gold antifade reagent with 
DAPI (Life Technologies) was added to the slide, and covered with a coverslip.  Antibodies 
used are listed below. 
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Antibody Company Catalog Number 
IL1 R&D MAB601 
IL1 R&D MAB200 
Anti-Mouse FITC Santa Cruz SC-2099 
Anti-Mouse TRITC Santa Cruz SC-2981 
 
Table 2: Antibodies used for Immunocytochemistry  
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2.6 Senescence-Associated -Galactosidase Staining 
A senescence detection kit (BioVision) was used for staining according to the 
manufacturer’s instructions. Briefly, treated cells were stained for senescence-associated 
β-galactosidase activity after 5-7 days of drug treatment. In order to count the senescence-
associated β-galactosidase positive cells, cell plates were washed twice with PBS and fixed 
with fixative solution for 10-15 minutes at room temperature. The fixed cells were washed 
with PBS and stained with the staining solution containing X-gal and staining supplement 
and incubated at 37oC overnight with no CO2. Cells containing blue stain were counted as 
senescent, proportionate to the total number of cells per field of vision.  At least 3 fields of 
vision were counted, with a minimum of 200 cells per plate.  Statistical significance was 
determined through student’s t-test and a p-value of less than 0.05 was considered 
significant.   
2.7 Cell Cycle Analysis 
Cell cycle analysis was performed using propidium iodide staining.  MDAH041 immortal cells 
were plated at 50% confluence.  On the next day, they were rinsed 3 times with PBS and given 
media supplemented with 0.1% FBS.  A control plate of immortal cells was also included which 
were supplemented with 10% FBS.  After 48 hours, cells were trypsinized and rinsed twice with 
PBS.  Pellet was resuspended in 1 mL PBS and added dropwise to 1 mL ice cold 95% ethanol, and 
stored overnight at 4oC.  Cells were rinsed twice with PBS, then pelleted again and 
resuspended in 500 uL staining solution: 10 mL 0.1% Triton x-100 in PBS with 0.4 mL 
500 ug/mL propidium iodide and 25 uL 10 mg/mL RNAase A and incubated for 37 oC for 
15 minutes.  After incubation, tubes were transferred to 4 oC and protected from light until 
flow cytometry was performed by the flow cytometry core at Wayne State University. 
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2.9 RNA-sequencing and Data Analysis 
Quality control for all RNA samples was performed on the Agilent 2100 
Bioanalyzer by the Applied Genomics Technology Center at Wayne State University.  
Measurements include RIN (RNA integrity number) and 28S/18S ratio.  RIN measured the 
degradation of RNA, as well any potential contamination with genomic DNA, and values 
close to 10 are optimal.  The 28S/18S ratio is measured through electrophoresis, and the 
ratio should be close to 2.  The size ratio of the 28S/18S ribosome is technically 2.7:1, or 
5kb:2kb but 2:1 is the benchmark for intact RNA. 
  Preparation of samples for sequencing was done at the AGTC using the TruSeq 
RNA sample preparation kit (Illumina).  Briefly, mRNA is taken from the total RNA by 
magnetic beads containing T oligos, which bind the 3’ poly A tails of mRNA, separating 
it from the total RNA.  The samples are fragmented by divalent cations and elevated 
temperature and reverse transcribed into cDNA.  The ends are repaired by addition of an 
“A” base and ligated to adapters which enable multiplexing of samples, and all fragments 
are enriched with PCR to get a final cDNA library.  In this sequencing run, the samples 
were multiplexed with 6 samples per lane, in 4 lanes, for a total of 24 samples.   
Samples were then sequenced on the Illumina HiSeq 2000 System, and analyzed 
by Dr. Adele Kruger at the AGTC.  Briefly, samples were demultiplexed with Illumina’s 
CASAVA 1.8.2 software (www.illumina.com) and quality control was assessed using 
FastQC from Babraham Bioinformatics (www.bioinformatics.babraham.ac.uk/).  Reads 
were then aligned to the Human Genome Consortium’s reference human genome hg19 [76] 
using Tophat software [77], allowing 20 alignments to the genome per sequencing read.  
Relative abundances and differential expression was calculated with Cufflinks [78].  
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Briefly, the Cuffdiff 2 feature of Cufflinks uses an algorithm that identifies differentially 
expressed genes by testing an observed fold change (calculated from FPKM values of 
different samples) against a null hypothesis (no change).  To account for variability, this 
program uses a model of variability which analyzes significance, through a table that 
predicts variance in number of gene reads for both conditions that are being compared.  
This algorithm eventually yields an estimate of the number of reads for each gene and a 
variance for that estimate, which are reported along with FPKM values and corresponding 
variance.  Differential expression if shown as fold change of FPKM, and the variance of 
FPKM allows the program to calculate variance for the fold change itself.  Therefore, a 
gene with variable expression will have a more variable fold change, and these variables 
are reflected in the resulting p-value. 
Pathway analysis was performed using Ingenuity Pathway Analysis (Ingenuity® 
Systems, www.ingenuity.com), Signaling Pathway Impact Analysis (SPIA) [79] with the 
help of Calin Voichita in the Computer Science Department, and Genomatix Genome 
Analyzer. 
Clustering analysis was performed using Cluster 3.0 software and Treeview 
software.  A hierarchical clustering was performed after log transforming the gene 
expression data (FPKM values or relative abundance).  The center median of the gene 
values were taken, and both the genes and arrays were clustered with an uncentered 
correlation and average linkage.  Results are presented as relative up-regulation or down-
regulation compared to the median expression of a given gene. 
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CHAPTER 3 
RESULTS 
3.1 Analysis of Samples for RNA-seq and RNA-seq 
 Eight RNA samples were obtained for potential RNA-seq: immortal cells 
(PD>200), lowest passage cells (PD 10-12), low passage cells (PD 17-19), replicatively 
senescent cells (PD 28-30), quiescent cells (PD>200, serum-starved), H2O2-induced 
senescent cells (PD>200, treated with H2O2), adriamycin-induced senescent cells 
(PD>200, treated with adriamycin), and 5-aza-induced senescent cells (PD>200, treated 
with 5-aza).  In order to perform RNA-seq, I first needed to confirm that the cells were 
senescent and the samples were high enough quality for sequencing.   
Senescence-associated -galactosidase staining was performed on simultaneous 
plates grown in parallel with those harvested for RNA to assess the amount of senescence 
in all samples (Figure 1).  Cell cycle analysis was performed on the quiescent samples to 
confirm withdrawal from the cell cycle (Figure 2). These RNA samples were transported 
to the Applied Genomics Technology Center, where quality control was performed to 
assess the amount of degradation of RNA and any potential contamination with genomic 
DNA (Figure 3).  After quality was ensured, the RNA was prepared for sequencing. 
In addition to quality control analysis performed by the Applied Genomics 
Technology Center, RT-PCR was performed on genes known to change during cellular 
senescence based on previous studies.  Cyclin A was shown to decrease in senescent 
samples, consistent with withdrawal from the cell cycle (Figure 4).  Additionally, interferon 
regulatory factors IRF3, IRF5 and IRF7 were examined to analyze the participation of the 
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interferon pathway in all types of senescence (Figures 5, 6, 7).  IRFs are transcription 
factors that can activate several members of the interferon pathway [80].   
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3.1.1 Senescence-Associated -Galactosidase Staining of RNA-seq Samples 
Senescence-associated -galactosidase staining was performed on all samples 
concurrent to RNA extraction (Figure 1).  All 4 types of senescence (natural, Adriamycin-
induced, 5-aza-induced and H2O2-induced) exhibited high levels of senescence-associated 
-galactosidase positive cells compared to the immortal and quiescent samples, which had 
only very low baseline levels of senescence-associated -galactosidase staining.  The 
difference in senescence-associated -galactosidase staining in the senescent samples was 
statistically significant compared to the immortal samples with p<.05 using a student’s t-
test.  Proliferating lowest passage cells and low passage cells showed a low level of 
senescence.  Three biological replicates were used for each condition.  This indicates that 
the 4 types of senescence were indeed senescent while the other conditions (immortal, 
quiescent, low passage, and lowest passage), were not senescent. 
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Figure 1: Senescence-Associated -galactosidase Activity Levels in RNA-seq Samples.  
All 4 types of senescence show a significantly higher level of SA--gal staining compared 
to the immortal, quiescent, lowest passage, and low passage samples.  Bars indicate 
percentage of total cells that are senescence-associated -galactosidase staining positive.  
Error bars represent three biological replicates. Statistical significance marked by astericks.   
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3.1.2 Cell Cycle Analysis of Quiescent Samples 
Cell cycle analysis was performed through propidium iodide staining to confirm 
cell cycle arrest in quiescent samples (Figure 2).  A plate of cells growing simultaneously 
to the plates harvested for RNA-seq was used for propidium iodide staining.  The quiescent 
samples showed increased levels of G1 and decreased levels of S phase compared to the 
proliferating immortal control, consistent with cell cycle arrest at G1/S.  Therefore these 
cells were confirmed to be quiescent and suitable for RNA-seq. 
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Figure 2: Cell Cycle Analysis of Quiescent Samples.  The quiescent MDAH041 cells 
show increased %G1 and decreased %S phase, indicating an accumulation of cells at 
G1/S, representing quiescence.  Dotted bars indicate immortal samples, squared bars 
indicate quiescent samples.  Results are shown as percentage of cells in each G1, S or G2 
phase via propidium iodide flow cytometry analysis.    
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3.1.3 Quality Control of RNA-seq Samples 
 Quality control was performed on all 24 samples used for RNA-seq (8 experimental 
cell conditions, in biological triplicate, to yield 24 samples).  Optimal samples have RIN 
(RNA integrity number) values close to 10 and 28S/18S ratios close to 2, as described in 
section 2.9).  All samples under consideration for RNA-seq exceeded values for quality 
control, with the exception of sample 8C which had a lower RIN than the rest of the 
samples, but was still deemed acceptable (Figure 3).  Therefore, all samples were then used 
for RNA-seq.  Sample 8C was later shown to have consistent gene expression levels with 
samples 8A and 8B, which validated the decision to include the sample in analysis. 
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Figure 3: RNA Integrity of RNA-seq Samples.  RIN (RNA Integrity Number) and 
28S/18S ratios are shown for each biological replicate of each condition.  Sample 8c was 
the only sample with a low RIN, but the RIN was not low enough to exclude the sample 
from sequencing. 
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3.1.4 Cyclin A Expression in RNA-seq Samples 
To further confirm that the 4 types of senescent cells were senescent, cell cycle 
withdrawal through RT-PCR analysis of Cyclin A was performed on all senescence types 
(Figure 4).  Previous studies in the Tainsky laboratory have shown that cyclin A expression 
decreases in various types of senescence because of cell cycle withdrawal that is incidental 
during senescence [36].  Cyclin A was down-regulated, in all 4 types of senescent cells 
compared to the proliferating immortal control.  This was consistent with previous studies, 
confirming these cells were senescent.  
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Figure 4: Cyclin A Expression in RNA-seq Samples.  All 4 types of senescent cells 
showed a decrease in Cyclin A2 expression compared to the immortal control.  Bars 
indicate RT-PCR log2 fold change of cyclin A compared to immortal cells.  Statistically 
significant changes relative to the immortal sample are marked with astericks.  Error bars 
indicate three biological replicates. 
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3.1.5 Interferon Regulatory Factor Expression in RNA-seq Samples  
Based on previous data from the Tainsky lab indicating the Interferon pathway is 
up-regulated during cellular senescence, RT-PCR analysis was performed on IRF3, IRF5 
and IRF7 from all senescence types to ascertain whether the interferon pathway was up-
regulated in all types of senescence (Figures 5, 6, 7).  IRF3 was down-regulated in H2O2 
and Natural senescence, and up-regulated in 5-aza-induced senescence (Figure 5).  In the 
RNA-seq data, IRF3 was not shown to be differentially expressed in any type of senescence 
compared to immortalization.  IRF5 was universally up-regulated compared to the 
immortal control, confirming a correlation of the interferon pathway and senescence 
(Figure 6).  In the RNA-seq data, IRF5 was not shown to be differentially expressed in any 
type of senescence compared to immortalization.  IRF7 showed up-regulation in 5-aza-
induced cells and natural senescence (Figure 7).  In the RNA-seq data, IRF7 was up-
regulated in natural senescence and 5-aza-induced senescence compared to the immortal 
control.  Additionally in the RNA-seq data, IRF9 was up-regulated in all 4 types of 
senescence compared to immortalization, however it was also shown to be up-regulated in 
quiescence at a similar level compared to immortalization, indicating this IRF may have a 
cell cycle related function.  RNA-seq data also showed IRF1 to be up-regulated in 
Adriamycin-induced, H2O2-induced and 5-aza-induced senescence compared to 
immortalization.  Each type of senescence exhibited a different profile of IRF expression, 
indicating a universal correlation of the interferon pathway in senescence but potential 
diversity of these interferon pathways in the various types of senescence.  
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Figure 5: Interferon Regulatory Factor 3 Expression in RNA-seq Samples.  IRF3 is 
down-regulated in H2O2-induced and naturally senescent cells, compared to immortal cells.  
Adriamycin shows no difference in IRF3 compared to immortal cells, and 5-aza-induced 
senescence shows up-regulation of IRF3 compared to immortal cells.  Bars indicate RT-
PCR log2 fold changes of IRF3 expression relative to the immortal sample.  Statistically 
significant changes from the immortal control are marked by astericks.  Error bars 
indicative of standard deviation of 3 biological replicates.  
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Figure 6: Interferon Regulatory Factor 5 Expression in RNA-seq Samples. IRF5 is up-
regulated in all 4 types of senescent cells compared to immortal cells.  Bars indicate RT-
PCR log2 fold changes of IRF5 expression relative to the immortal sample.  Statistically 
significant changes from the immortal control are marked by astericks.  Error bars 
indicative of standard deviation of 3 biological replicates. 
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Figure 7: Interferon Regulatory Factor 7 Expression in RNA-seq Samples. IRF7 is up-
regulated in 5-aza-induced and naturally senescent cells compared to immortal cells.  H2O2 
doesn’t show a significant different in IRF7 expression compared to immortal cells.  
Adriamycin-induced senescence shows down-regulation of IRF7 compared to immortal 
cells.  Bars indicate RT-PCR log2 fold changes of IRF7 expression relative to the immortal 
sample.  Statistically significant changes from the immortal control are marked by 
astericks.  Error bars indicative of standard deviation of 3 biological replicates.  
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3.2 RNA-seq Analysis and Clustering 
RNA was sequenced as described in the methods section.  First, differentially 
expressed genes in all types of senescence compared to the immortal control were 
examined.  Differentially expressed genes were those that had a +/-2 fold change relative 
to the control with a p-value of less than 0.05.  The intersection of all 4 types of senescence, 
or genes that were differentially expressed in all 4 types of senescence yielded 93 genes 
(Figure 8).  However, the genes that were differentially expressed in quiescent cells 
compared to the immortal control were removed from this population of genes in an effort 
to remove the number of genes that were differentially expressed only due to withdrawal 
from cell cycle (quiescence) during senescence leaving those that were senescence-
specific.  Therefore, 45 genes were subtracted from the population, leaving a final list of 
48 genes that were differentially expressed in all 4 types of senescence compared to 
immortalization, but not differentially expressed in quiescence compared to 
immortalization.   
Pathway analysis was performed using a variety of programs, including Genomatix 
Genome Analyzer (GGA), Ingenuity Pathway Analysis (IPA) and Signaling Pathway 
Impact Analysis (SPIA).  SPIA analysis was performed by collaborators in the Computer 
Science Department.  Initially, Genomatix analysis showed the most probable pathways 
involved with senescence to be the immune system and interferon related pathways, which 
is consistent with previous results from the Tainsky laboratory.  To confirm these results, 
IPA analysis was also performed.  This type of analysis gave the same results, indicating 
the immune system and interferon pathways to play a large role in senescence based on the 
48 genes studied and showing it is not a software-dependent finding.   
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Clustering analysis was performed using Cluster 3.0 software and Treeview 
software (Figure 9, 10, 12, 13, 16) to compare patterns of gene expression among various 
samples.  This type of analysis showed that the 4 types of senescent cells had different gene 
expression profiles than immortalization, and that the quiescent cells showed a different 
gene expression profile than the senescent cells.  Additionally, a progression from lowest 
passage cells to low passage cells to natural senescence can be observed in the form of 
progressive up-regulation of certain genes associated with senescence.   
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3.2.1 Comparison of Differentially Expressed Genes 
5-aza-induced senescent cells had 3990 genes that were differentially expressed 
compared to the immortal control (Figure 8).  2449 were up-regulated and 1350 were 
down-regulated.  The adriamycin-induced group had 1425 genes that were differentially 
expressed compared to the immortal control, where 1067 genes were down-regulated and 
358 were up-regulated.  Naturally senescent had 2729 genes that were differentially 
expressed compared to the immortal cells, 1379 down-regulated and 1350 up-regulated.  
H2O2 senescent cells had 193 genes that were differentially expressed, 14 down-regulated 
and 179 up-regulated.  The intersection of these 4 conditions yielded a list of 93 genes that 
were differentially expressed in all 4 types of senescence.  Forty-five genes that were 
differentially expressed in quiescent cells compared to immortal cells were subtracted from 
the 93 genes in order to account for changes due only to the withdrawal from cell cycle.  
This yielded a total of 48 genes that were differentially expressed in all four types of 
senescence but not in quiescence.   
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Figure 8: Comparison of Differentially Expressed Genes.  The differential gene 
expression in 4 types of senescence compared to immortalization.  Black numbers indicate 
number of differentially expressed genes between the given sample and immortal sample, 
red number indicates number of genes up-regulated in the given sample compared to the 
immortal sample, and green numbers indicate number of genes down-regulated in the given 
sample compared to the immortal control.  Dark gray portions indicate overlap between 
samples, and the red center indicates overlap between all 4 types of senescence.  Red 
numbers show up-regulated genes and green show down-regulated genes. 
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3.2.2 Clustering Analysis of 45 Genes Differentially Expressed in Quiescent and 
Senescent RNA-seq Samples 
Clustering analysis of the 45 genes differentially expressed in quiescent cells, 
immortal cells as well as all 4 types of senescent cells was performed.  Interestingly, the 
quiescent gene expression was most similar to the immortal gene expression and very 
different from the senescent gene expression, which reinforced the validity of removing 
the quiescent genes from senescence-associated pathway analysis (Figure 9). 
The 45 genes were also clustered with the immortal sample being compared to the 
low passage and lowest passage samples, as well as natural senescence (Figure 10).  The 
immortal sample associated closest to the lowest passage sample, which is consistent with 
the idea that these genes are down-regulated during cell growth and up-regulated during 
senescence.  The low passage sample which are proliferating at a slower rate due to 
impending senescence associated closest to natural senescence, again indicating that these 
genes are up-regulated as a cell ages. 
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Figure 9: Clustering Analysis in Immortalization and Senescence of the 45 Quiescent-
Associated Genes.  The 45 quiescence-associated genes are mostly up-regulated in all 4 
types of senescence and down-regulated in quiescence and immortalization.  Green bars 
show relative down-regulation and red shows relative up-regulation compared to the 
median expression of a given gene.  Expression from all 4 types of senescence, quiescence 
and immortalization are shown. 
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Figure 10: Clustering Analysis in Immortalization and Aging Samples of the 45 
Quiescent-Associated Genes.  The 45 quiescence-associated genes were mostly up-
regulated in low passage aged cells and naturally senescent cells, and mostly down-
regulated in quiescent cells and immortal cells that are still proliferating.  The genes were 
clustered to show comparison of the genes between immortal, low passage, lowest passage 
and natural senescence.   Green bars show relative down-regulation and red shows relative 
up-regulation compared to the median expression of a given gene. 
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3.2.3 Forty-Eight Genes Differentially Expressed in all 4 Types of Senescence 
There were 48 genes that were deemed senescence-associated based on their 
differential expression in all 4 types of senescence compared to immortalization and 
absence of differential expression in quiescence compared to immortalization (Figure 11).  
Clustering was first performed on the 48 genes found to be differentially expressed in all 
four types of senescence compared to immortalization (Figure 12).  This showed an inverse 
relationship between senescence and immortalization, which was expected.  The genes that 
were highly up-regulated in all 4 types of senescence were down-regulated in 
immortalization, and the genes that were highly up-regulated in immortalization were 
down-regulated in all 4 types of senescence.  5-aza-induced senescence shows a higher up-
regulation of most genes compared to the other types of senescence.  This data shows the 
inverse relationship between senescence and immortalization and further confirms the 
validity of this RNA-seq dataset. 
 Additionally, these 48 genes were clustered for early lowest passage cells and low 
passage cells, as well as natural senescence and immortalization in order to analyze the 
relationship (Figure 13).This showed the closest relationship between immortalization and 
early low passage cells, which is not surprising seeing that both sets of cells are 
proliferating.  Additionally, the natural senescent cells were most closely associated with 
the low passage cells, which is not surprising seeing that the low passage cells are aged and 
approaching senescence, therefore not proliferating very much.  Additionally, a 
progressional up-regulation of genes from lowest passage, to low passage, to natural 
senescence can be observed which indicates that several senescence-associated genes 
become increasingly activated as the cell ages.   
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Figure 11: 48 Genes Senescence-Associated Genes.  48 genes were deemed senescence-
associated because they were differentially expressed in all 4 types of senescence compared 
to immortalization, but not differentially expressed in quiescence compared to 
immortalization.  After pathway analysis indicated a role for immune system  pathways in 
senescence, the list was updated to show genes related to the immune system in red.  
Additionally, genes listed with an asterick indicate genes that are part of the senescence-
associated secretory phenotype.  
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Figure 12: Clustering Analysis in Immortalization and Senescence of the 48 
Senescence-Associated Genes.  Immortal cells show an inverse relationship compared to 
the 4 types of senescence.  Genes down-regulated in immortalization are up-regulated in 
senescence, and genes up-regulated in immortalization are down-regulated in senescence.  
Immortal sample and all 4 types of senescence are shown here.  Green bar indicates relative 
down-regulation and red bars indicate relative up-regulation relative to the median 
expression of a given gene. 
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Figure 13: Clustering Analysis in Immortalization and Aged Samples of 48 
Senescence-Associated Genes.  Most of the 48 senescence-associated genes become 
increasingly up-regulated as a cell ages and approaches senescence.  Immortal sample, low 
passage, lowest passage and natural senescent samples are shown here.  Green bars indicate 
relative down-regulation and red bars indicate relative up-regulation compared to median 
expression of a given gene. 
59 
 
 
 
3.3 The Interferon/Inflammatory Pathway is Differentially Expressed in 4 Types of 
Senescence 
 After identification of the 93 genes that were differentially expressed in all types of 
senescence, the 45 genes that were also differentially expressed in quiescence were 
subtracted to yield a total of 48 genes that were differentially expressed in all 4 types of 
senescence but not associated with quiescence.  Cluster analysis from section 3.2 (Figure 
9) validated the decision to remove the 45 genes from senescence-associated pathway 
analysis because the quiescent sample associated most closely to the immortal sample for 
these 45 genes, indicating that the quiescent samples were different from the senescent 
samples.  The resulting 48 genes (Figure 11) after subtraction of the 45 quiescent genes 
were used for pathway analysis through Genomatix Genome Analyzer and Ingenuity 
Pathway Analysis. 
 Pathway analysis through both types of software indicated immune system 
pathways to be highly significant for these 48 genes, indicating a possible role for the 
immune system/inflammatory pathways in all 4 types of senescence (Tables 3 and 4).  This 
finding is consistent with previous data from the Tainsky laboratory, also showing a role 
for the Interferon/Inflammatory pathway in senescence.  All genes from the interferon 
pathway and IL1 pathway, shown below, were up-regulated in the dataset in all 4 types of 
senescence compared to immortalization.  A schematic of the genes included in the 
“inflammation” pathway according to Genomatix is shown in Figure 14.  All of the genes 
within this pathway were up-regulated in senescent cells.  Figure 15 shows a schematic of 
the “defense response” pathway according to Genomatix.  All genes in this pathway were 
also up-regulated in senescent cells compared to immortal cells. 
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 Because of previous Tainsky lab data showing a role for the interferon regulatory 
factors in 5-aza-induced senescence, I analyzed the presence of IRFs in all 4 types of 
senescence through clustering analysis (Figure 16).  The 5-aza-induced senescence sample 
associated similarly with the natural senescenct sample, indicating a similarity between the 
two types of senescence.  The analysis also showed a down-regulation of most IRFs in 
immortalized cells compared to the 4 types of senescent cells, which was expected due to 
the increased activity of IRFs in 5-aza-induced senescence that the Tainsky lab previously 
showed.  The 5-aza-induced senescence sample exhibited an up-regulation of IRF6 and 
IRF7, which is consistent with RT-PCR shown above which shows high up-regulation of 
IRF7 in this sample.  Additionally, natural senescence showed high expression of IRF4 and 
IRF7, which again is consistent with above RT-PCR data showing high levels of IRF7 in 
the natural sample.  Adriamycin showed high levels of IRF3, which was not confirmed in 
my RT-PCR data.  
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Table 3:  Genomatix Pathway Analysis of the 48 Senescence-Associated Genes. The 
48 senescence-associated genes are involved with immune system pathways.  The top 20 
pathways represented by the 48 genes common to all types of senescence but not 
quiescence according to Genomatix analysis are shown here, sorted from lowest p-value to 
highest p-value.  All pathways are statistically significant.   
  
Genomatix Pathway P-value
defense response 3.76E-13
immune response 4.22E-12
immune system process 6.55E-10
cytokine-mediated signaling pathway 6.76E-10
cellular response to cytokine stimulus 1.55E-09
response to stress 2.86E-09
inflammatory response 8.54E-09
response to cytokine stimulus 2.74E-08
innate immune response 3.65E-08
response to wounding 4.60E-07
response to organic substance 1.57E-06
cellular response to organic substance 2.20E-06
regulation of I-kappaB kinase/NF-kappaB cascade 3.72E-06
cell surface receptor linked signaling pathway 5.55E-06
response to stimulus 6.40E-06
response to molecule of bacterial origin 6.51E-06
positive regulation vascular endothelial growth factor production 7.55E-06
response to chemical stimulus 7.77E-06
multi-organism process 8.67E-06
regulation of interleukin-6 production 1.15E-05
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Ingenuity Pathway P-value
Dendritic Cell Maturation 0.00525
Role of Cytokines in Mediating Communication between Immune Cells 0.00687
Atherosclerosis Signaling 0.00799
NF-κB Signaling 0.015
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis 0.0194
Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza 0.0231
Graft-versus-Host Disease Signaling 0.0262
IL-6 Signaling 0.0271
Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis 0.0287
LXR/RXR Activation 0.0311
TREM1 Signaling 0.0391
Hepatic Cholestasis 0.0391
IL-10 Signaling 0.0478
Acute Phase Response Signaling 0.049
Altered T Cell and B Cell Signaling in Rheumatoid Arthritis 0.0555
Communication between Innate and Adaptive Immune Cells 0.0572
Differential Regulation of Cytokine Production in Intestinal Epithelial Cells by IL-17A and IL-17F 0.062
PPAR Signaling 0.0639
FXR/RXR Activation 0.0665
IL-1 Signaling 0.0665
 
Table 4: Ingenuity Pathway Analysis of the 48 Senescence-Associated Genes.  The 48 
senescence-associated genes again are shown to be involved with immune system 
pathways.  The top 20 pathways represented by these genes according to Ingenuity 
Pathway Analysis are shown here, sorted from lowest p-value to highest p-value.  Fourteen 
pathways are statistically significant.   
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Figure 14: Inflammatory Pathway Activity According to RNA-seq Data. The 
inflammatory pathway was one of the most significant pathways to be important in all types 
of senescence compared to immortalization.  Shown here is a network of the inflammatory 
pathway genes that were in all 4 types of senescence based on the RNA-seq data.  Arrows 
indicate activation, and dashed lines indicate experimental validation.  All of these genes 
were up-regulated in the 4 types of senescence compared to immortalization.  Figure drawn 
using Genomatix. 
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Figure 15: Defense Response Activity According to RNA-seq Data.  Defense response 
was another highly significant pathway shown to be related to all 4 types of senescence.  
As shown above, the genes indicated in this pathway have a variety of complex 
interactions.  Arrows indicate activation, while dashed lines indicate experimental 
validation.  All of these genes were up-regulated in the 4 types of senescence compared to 
immortalization. Figure drawn using Genomatix. 
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Figure 16: Cluster Analysis of Interferon Regulatory Factors in Senescence and 
Immortalization.  IRF expression is variable among the different types of senescence, but 
as a whole, shows up-regulation in senescence compared to the immortal cells.  Immortal, 
5-aza, adria, and H2O2 samples are shown.  Red bars indicate up-regulation and green bars 
indicate down-regulation compared to the median expression of a given gene.  
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3.4 RNA-seq Demonstrates the Significance of the IL1 Pathway in All Types of 
Senescence 
After showing the interferon pathway’s presence in all 4 types of senescence 
through Genomatix and IPA analysis based on the 48 genes in common in all types of 
senescence but not quiescence, a slightly different approach was used to identify pathways.  
Signalling Pathway Impact Analysis was performed by the WSU Applied Genomics 
Technology Center, specifically Dr. Calin Voichita performed the analysis under the 
supervision of Professor Sorin Draghici, Department of Computer Science, WSU.  Dr. 
Voichita performed SPIA analysis on all genes differentially expressed in all types of 
cellular senescence.  SPIA, or Signaling Pathway Impact Analysis, identifies significant 
pathways based on over-representation of differentially expressed genes in pathways, as 
well as abnormal changes in pathways measured by changes across pathway topology [79].  
This type of analysis is different from Genomatix and Ingenuity, which rely on gene set 
enrichment analysis (GSEA).  Based on the genes differentially expressed in the 4 types of 
senescence compared to immortalization, the top 9 pathways that were given all involved 
the interferon and immune system pathways that were identified previously (Table 5).  
Based on these 9 pathways, the genes that comprised these pathways were extracted and 
the genes present in all 4 types of senescence were considered for further study.  This 
consisted of 9 genes that were interferon related and involved with cellular senescence 
(Tables 6 and 7).  These 9 genes represent a subset of genes also identified in the previous 
identification of 48 genes that were considered senescence-associated.  However IL8 (one 
of the 9 genes identified) was not included in the list of 48 genes because it was also 
differentially expressed in quiescence.  However, upon further examination, this gene was 
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actually down-regulated in quiescence compared to immortalization, while being up-
regulated during senescence, so while it was omitted from the original list of 48 
senescence-associated genes, it is indeed senescence-associated. 
Five out of 9 of the identified interferon-related genes were present in one pathway, 
which was the interleukin 1 pathway.  These genes were shown to be up-regulated in 
senescence compared to immortalization in MDAH041 cells through RT-PCR, and IL1 
and Il1 were shown to be up-regulated in 3 types of induced senescence compared to 
immortalization at a protein level in MDAH041 cells through immunocytochemistry.  I 
performed additional confirmation of this pathway through RT-PCR of MDAH087-N and 
MDAH087-1 cells, which showed up-regulation of IL1 and IL1 in the 3 types of induced 
senescence compared to immortalization.  The Il1 pathway was therefore confirmed to be 
up-regulated in 4 types of senescence compared to immortalization in multiple cell lines. 
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Table 5: Signaling Pathway Impact Analysis Reveals Inflammatory Pathways in all 4 
Types of Senescence.  Shown here are the 9 statistically significant pathways represented 
in at least one type of senescence as determined by SPIA.  There were 209 genes that 
comprised these pathways.  These genes were then further analyzed to identify the genes 
that were differentially expressed in all 4 types of senescence.  This yielded a total of 9 
genes that were considered for further study. 
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Table 6: Nine Genes Differentially Expressed in all 4 Types of Senescence According 
to SPIA Analysis of Senescent Pathways.  These genes are present in the 9 pathways 
listed in table 5 and are differentially expressed in all 4 types of senescence compared to 
immortalization.  The genes shown in red are all members of the IL1 pathway and were 
chosen for further analysis. 
  
70 
 
 
 
 
Table 7: Gene Expression of the IL1 Pathway According to RNA-seq Data.  Five 
members of the IL1 pathway were up-regulated in all 4 types of senescence compared to 
immortalization.  Log2 Fold changes in all four types of senescence for 5 of the 9 genes 
indicated by SPIA analysis to be important in senescence.  These values represent 
differential expression analysis of the original RNA-seq data, with each condition 
normalized to the immortal control.  All 5 of the genes were up-regulated compared to the 
immortal control. 
  
H2O2 Adria Nat 5-aza
IL1a 5.82 3.44 5.98 8.87
IL1b 6.38 3.75 4.58 9.57
Myd88 1.92 1.32 1.26 1.62
ICAM1 3.95 2.94 3.73 7.23
IL8 5.55 3.10 2.78 7.28
71 
 
 
 
 
 
 
Figure 17: IL1 Pathway Activity According to RNA-Seq Data.  The Interleukin 1 
pathway was a significant pathway in all types of senescence according to the Genomatix 
Genome Analyzer.  Arrows indicate activation, while dashed lines indicate experimental 
validation.  IL1, IL1 and IL1RN (IL1 receptor antagonist) all bind the IL1R (IL1 
receptor), and then interact with the adapter protein Myd88.  The IL1R did not show 
differential expression in our RNA-seq data.  
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3.5 Confirmation of the IL1 Pathway in All Types of Cellular Senescence 
 In order to validate the RNA-seq data, RT-PCR was performed to confirm the up-
regulation of the Il1 pathway in all 4 types of cellular senescence.  The up-regulation of 
IL1, IL1, Myd88, ICAM1 and IL8 were all confirmed in the MDAH041 cells (Figures 
18 and 19), and IL1 and IL1 were confirmed in induced senescence of the MDAH087-
1 and MDAH087-N cells (Figures 20 and 21).  Naturally senescent samples were not 
obtained for MDAH087 because the cells progress from decreased growth into a state of 
crisis where they proliferate quickly, and therefore an accurately senescent sample was not 
attainable.  In addition to RT-PCR, protein levels were also assessed using 
immunocytochemistry of MDAH041 cells.  Natural senescence was not included in the 
protein analysis of the IL1 pathway because they could not be plated on chamber slides 
properly.  If plated too early while the cells are not senescent, the cells will become too 
confluent for protein analysis, and if plated during senescence, the cells will not adhere to 
the plate.  Additionally, naturally senescent MDAH087 cells were not included in RT-PCR 
analysis because of their difficulty to obtain.  The MDAH087 cells typically stop 
proflieration in senescence very briefly, and enter crisis where they begin proliferating 
again, making isoluation of naturally senescent MDAH087 cells difficult.   
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Figure 18: IL1 and Il1 Expression in MDAH041 Cells.  IL1 and Il1 were both up-
regulated in all 4 types of senescence compared to immortalization in the MDAH041 cells.   
Changes shown are RT-PCR Log2 fold changes relative to immortalization.  Error bars 
indicate standard deviation of 3 biological replicates and astericks indicate a significant 
difference from immortalization with p<0.05. 
74 
 
 
 
 
Figure 19: Myd88, ICAM1 and IL8 Expression in MDAH041 Cells.  Myd88, ICAM1 
and IL8 were all up-regulated in all 4 types of senescence compared to immortalization in 
the MDAH041 cells.  Values shown are log2 fold changes in MDAH041 cells relative to 
immortalization.  Error bars indicate standard deviation of 3 biological replicates and 
astericks indicate a significant difference from immortalization with p<0.05. 
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Figure 20: IL1 and Il1 Expression in MDAH087-1 Cells. IL1 and Il1 were up-
regulated in the 3 types of induced senescence compared to immortalization in the 087-1 
cells.  Values shown are log2 fold changes compared to immortal MDAH087-1 cells.  Error 
bars are indicative of standard deviation of 3 biological replicates and astericks indicate 
significant difference compared to immortalization with p<0.05. 
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Figure 21: IL1 and IL1 Expression in MDAH087-N Cells.  IL1 and Il1 were up-
regulated in the 3 types of induced senescence compared to immortalization in the 087-N 
cells.  Values shown are log2 fold changes compared to immortal MDAH087-N cells.  Error 
bars indicate standard deviation of 3 biological replicates and astericks represent a 
significant difference from immortalization with p<0.05. 
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Figure 22: Immunocytochemistry Analysis of Il1 Protein Levels in MDAH041 Cells.  
IL1 was up-regulated at a protein level in the 3 types of induced senescence compared to 
immortalization.  Blue staining indicates DAPI (top row), green staining indicates IL1 
(middle row) and the bottom row shows a merged representation of both stainings.    
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Figure 23: Immunocytochemistry Analysis of Il1 Protein Levels in MDAH041 Cells.  
IL1 is up-regulated at a protein level in the 3 types of induced senescence compared to 
immortalization.  Blue staining indicates DAPI (top row), red staining indicates IL1 
(middle row) and the bottom row shows a merged representation of both stainings. 
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3.6 Histone Modifications in Senescence 
 Signaling Pathway Impact Analysis, or SPIA was performed with the help of the 
Wayne State University Computer Science Department on the differentially expressed 
genes in invidivual types of senescence compared to immortalization in order to elucidate 
any pathways unique to each type of senescence.  I chose to focus on adriamycin-induced 
senescence because of its relevance to cancer chemotherapy.  Adriamycin-induced 
senescence yielded the histone modification or chromatin modification pathway in this 
specific type of senescence.  Based on this analysis, a list of genes involved with chromatin 
modification were elucidated from the SPIA software, and a table of values was composed 
consisting of the different values of each gene (Table 8).   
Clustering analysis of these genes was performed (Figure 24). The first column, 
which represents adriamycin-induced changes in gene expression, show a greater down-
regulation of most genes than the other three types of senescence, which for the most part 
show only small levels of up-regulation or down-regulation of the genes related to 
adriamycin-induced senescence. 
 PRDM9 was analyzed, based on its high up-regulation in adriamycin-induced 
senescence.  PRDM9 is a histone H3 methyltransferase, which contains a PR domain [81].  
This protein is thought to dictate genetic recombination hotspots through its sequence-
specific binding to zinc finger domains [82].  Specifically, PRDM9 trimethylates H3K4, 
which is typically a histone mark that indicates active transcription.  Therefore, PRDM9 
was an interesting candidate for regulation of senescence because up-regulation of an 
active histone mark during senescence could cause increased expression of senescence 
genes.  PRDM9 was confirmed to be upregulated in adriamycin-induced senescence 
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compared to the immortal control, however it was also upregulated in 5-aza-induced 
senescence and H2O2-induced senescence (Figure 25).  It appeared to be down-regulated 
in natural senescence.  This may represent a unique method of induction of senescence in 
adriamycin treated cells. 
Additionally, SUV420H1 was analyzed based on its down-regulation in 
adriamycin-induced senescence.  This gene was chosen based on having one of the highest 
down-regulations of the chromatin modification genes, as well as its known activity as a 
methyltransferase.  SUV420H1 is a histone H4K20 methyltransferase and contains a SET 
domain which allows for interactions with other proteins [83].  Specifically, SUV420H1 
trimethylates H4K20, which is typically a repressive histone mark.  Therefore, SUV420H1 
was an interesting candidate for the regulation of senescence bceause down-regulation of 
a respressive histone mark during senescence could cause increased expression of a given 
gene during cellular senescence.  It was confirmed to be down-regulated in adriamycin-
induced senescence, however it was also downregulated in H2O2-induced senescence, 5-
aza induced senescence, and natural senescence (Figure 26).  Based on the large amount of 
chromatin modifying genes differentially expressed in adriamycin-induced senescence, as 
well as the confirmation of two genes, it is probable that adriamycin-induced senescence 
involves chromatin remodeling, which is a novel method of induction of senescence for 
this agent, and is similar to the mechanism of 5-aza-induced senescence.  5-aza-induced 
senescence is essentially an epigenetic reversal of immortalization, as 5-aza is an inhibitor 
of DNA methyltransferase, and was shown to cause re-activation of several interferon 
genes upon treatment of immortal cells [49]. 
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Table 8: Chromatin Modification Genes Differentially Expressed in adriamycin-
induced Senescence.  Log2 fold change determined by RNA-seq for each chromatin 
modifying gene as well as probable functions are listed.  This chromatin modification of 
adriamycin-induced senescence could represent a novel mechanism of induction of 
senescence for adriamycin.   
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Figure 24: Clustering Analysis of the Genes Shown to be Unique to adriamcyin-
induced senescence. Adriamycin-induced senescence shows a slight down-regulation of 
most chromatin modifying genes compared to the other 3 types of senescence.  Green bars 
indicate relative down-regulation and red bars indicate relative up-regulation compared to 
median expression for a given gene.   
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Figure 25: PRDM9 Expression in MDAH041 Cells.  PRDM9 was up-regulated in the 3 
types of induced senescence compared to immortalization, but down-regulated in natural 
senescence compared to immortalization.  Changes shown are log2 fold changes of PRDM9 
relative to immortalization.  Error bars indicate standard deviation of 3 biological 
replicates.  Astericks indicate statistically different changes from the immortal control 
where p<0.05. 
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Figure 26: SUV420H1 Expression in MDAH041 Cells.  SUV420H1 is down-regulated 
in all 4 types of senescence compared to immortalization.  Changes shown are log2 fold 
changes relative to immortalization.  Error bars indicate standard deviation of 3 biological 
replicates.  Astericks indicate stastistically significant changes from immortalization with 
p<0.05. 
  
* 
* 
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3.7 Senescence Associated Secretory Phenotype Profiles 
 The senescence associated secretory phenotype is a group of secreted factors 
released from senescent cells into the microenvironment.  The RNA-seq data was analyzed 
for the presence of all known SASP factors [84].  These factors are grouped into three 
categories by their regulation: High increase (4+ fold change), intermediate increase (2-4 
fold change) and small increase (below 2 fold change) based on previous studies 
establishing these changes.   In order to assess the differences in the senescence associated 
secretory phenotype profiles among the different types of senescence, as well as the 
immortal control, clustering analysis was performed of the genes that make up the pathway.  
Analysis was performed using each category (high increase, intermediate increase and low 
increase) separately, and with all the categories of genes together to see overall changes.   
 Clustering analysis of all genes showed immortalization to have a high number of 
downregulated genes, whereas the multiple types of senescence show an increase in several 
of the genes (Figure 27).  Firstly, this confirms the senescent phenotype of the senescent 
cells, especially when compared to the immortal control which shows downregulation of 
these genes.  Secondly, this clustering analysis shows that again the naturally senescent 
cells group most closely with the 5-aza-treated senescent cells, showing that 5-aza-induced 
senescence mimics the natural aging process of DNA demethylation.  Aging cells have 
been shown to have decreased amounts of methylation with age, whereas immortal cells 
maintain methylation [85].  Therefore, the 5-aza induced senescence resembles natural 
senescence. 
 Clustering analysis of SASP components with high fold changes was performed 
(Figure 28).  Accordingly, the immortal control shows downregulation of every gene listed 
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(with exception of two which no values were found) and the senescent samples show 
upregulation of these SASP genes.  5-aza showed the highest number of upregulated genes, 
indicating a very strong SASP response, whereas adriamycin treatment didn’t show as 
much of the SASP as expected, given that DNA damage is known to cause a SASP 
response.   
 Clustering analysis of the SASP components with intermediate fold change 
revealed that again the immortal control has several of these genes downregulated, and the 
senescent samples have them upregulated (Figure 29).  5-aza again shows the highest 
amount of upregulation, indicating a strong SASP response.  Adriamycin treated cells again 
don’t show a high amount of upregulation as expected, given that DNA damage is a known 
cause of SASP [41].  There were 5 genes from this group of SASP members that were not 
found in our dataset (gray boxes).   
 Lastly, clustering analysis of SASP components with small fold changes was 
performed (Figure 30).  There were a large number of genes in this group that were not 
found in our dataset (gray boxes).  The immortal control again shows downregulation of 
most of the genes that were found in the dataset, while the senescent samples show 
upregulation of these genes.  Again, the 5-aza treated sample shows the highest amount of 
upregulation and a therefore a strong senescent response.  Adriamycin shows a large 
number that were upregulated, but also a fair amount that were downregulated.  This is 
somewhat unexpected as DNA damage is known to cause a SASP response. 
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Figure 27: Clustering Analysis of all Known SASP Components.  All known 
senescence associated secretory phenotype genes in all types of senescence and 
immortalization.  Empty gray boxes indicate that the gene was not found in the given 
sample according to RNA-seq.  12 genes were not shown based on not being present in 
RNA-seq data for any of the samples.  They were: GCP2, TNFRSF18, NAP2, OPG, 
SPG130, ACRP30, BLC, CCL16, MSP-a, SERPINEB2, SCF, and VEGF. 
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Figure 28: Clustering Analysis of SASP Components with High Fold Changes.  
Senescent associated secretory phenotype genes with typically high fold changes, as 
described by Freund et al. [84].  Gray boxes indicate where a value was not found for a 
given gene in our dataset.  Red boxes indicate relative up-regulation while green boxes 
indicate relative down-regulation compared to the median expression for a given gene. 
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Figure 29: Clustering Analysis of SASP Components with Intermediate Fold Change.  
Senescent associated secretory phenotype genes with an intermediate fold change as 
described by Freund at al [84].  Gray boxes indicate that no value was found in our data 
for the given gene.  Red boxes indicate relative up-regulation while green boxes indicate 
relative down-regulation compared to the median expression for a given gene. 
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Figure 30: Clustering Analysis of SASP Components with Small Fold Change.  
Senescent associated secretory phenotype genes with a small upregulation according to 
Freund et al. [84].  Gray boxes indicate that no value was found in our data.  Red boxes 
indicate relative up-regulation while green boxes indicate relative down-regulation 
compared to the median expression for a given gene. 
  
91 
 
 
 
CHAPTER 4 
DISCUSSION 
4.1 Goal of Study  
Cellular senescence during aging is believed to be a tumor suppressive mechanism, 
through limiting the replication of a cell and thereby preventing acquisition of hazardous 
mutations [86].  Senescence can protect the cell from replicating once an oncogene is 
activated, again serving as a protective mechanism [30].  However, senescence also occurs 
in response to other stressors, such as chemotherapeutic agents and oxidative stress, which 
can hinder therapeutic response [52].  Given the various mechanisms that generate 
senescent cells, it was important to understand these different types of senescence and 
compare their pathways by gene expression profiling.  Previous gene expression studies of 
cellular senescence have typically focused on a single mechanism of senescence, such as 
oncogene-induced senescence or senescence induced by radiation.  In this thesis research, 
I utilized a cellular model that allowed comparison of multiple types of senescence within 
one cell line, allowing me to contrast natural or replicative senescence and induced 
senescence, as well as compare senescence and immortalization without confounding 
issues of genetic variation among cell lines.   
4.2 The Role of the Inflammation and SASP in Senescence 
 Further complicating the understanding of senescence is the senescence-associated 
secretory phenotype, which involves a set of more than 70 secreted factors from most 
senescent cells that can cause inflammation, bystander senescence, and even 
transformation of surrounding pre-malignant cells [70].  Previously in the Tainsky 
laboratory, gene expression profiling was used to study epigenetic regulation of gene 
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expression during immortalization by comparison to 5-aza-2’-deoxycytidine-induced 
senescence.  Those studies showed dysregulation of the cytoskeletal pathway, cell cycle 
pathway, and interferon pathway [22].  While the cytoskeletal pathway and cell cycle 
pathway gene expression changes were expected due to changes in cell morphology and 
withdrawal from the cell cycle during senescence, the interferon pathway was an 
unexpected finding.  This role for the interferon pathway during cellular senescence that 
was identified by our lab has been cited as early evidence for presence of the senescence-
associated secretory phenotype [41].  RNA-seq analysis of 4 types of senescence in the 
present thesis research has shown that up-regulation of the interferon pathway is present in 
all 4 types of senescence, and therefore it is likely that the senescence-associated secretory 
phenotype is also present in all types of senescence.  Clustering analysis revealed that each 
type of senescence had at least some SASP factors up-regulated, although the exact SASP 
profiles were not consistent between samples.  For example, 5-aza-induced senescence, 
natural senescence, and H2O2-induced senescence all had large numbers of genes up-
regulated compared to immortal cells, but not the same genes.  This could indicate that 
while various types of senescence utilize the same mechanisms and characteristics (such 
as SASP), the specific genes involved in these processes may vary. 
Since the Tainsky study was published in 2003 showing a role for the interferon 
pathway in 5-aza-induced senescence, others have shown results consistent with those 
findings that interferon-related genes are up-regulated during senescence, but the reason 
for this is still largely unknown, with the exception of the hypothesis that the senescence-
associated secretory phenotype relies on these gene expression changes [60, 64, 66, 69, 
87].  Our lab has since shown various transcriptional regulators of the 
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interferon/inflammatory pathway can cause senescence when exogenously expressed, 
specifically IRF5 and IRF7 [45].  This thesis, utilizing RNA-seq analysis of multiple types 
of senescence, provides evidence that the interferon/inflammatory pathway is involved in 
all types of senescence studied (Natural, 5-aza, adriamycin, and H2O2), through pathway 
analysis, clustering analysis, and RT-PCR validation of gene expression.  The pathway 
analysis of senescence-associated genes was consistent among 3 different software 
approaches (Tables 3, 4, 5), which reinforces the finding that the inflammatory pathway is 
important in all types of senescence, and not software-dependent.  Clustering analysis of 
senescence-associated interferon genes, including the IRFs, showed that again the pathway 
itself is up-regulated but the same genes are not always up-regulated from mechanism to 
mechanism, indicating a universally necessary pathway with variable gene involvement.   
In conjunction with pathway analysis of the 48 genes in common in all 4 types of 
senescence, which indicated the interferon/inflammatory pathway, I also compared our 
data to a list of known senescence-associated secretory phenotype genes to assess the level 
of secreted factors in each type of senescence.  There were a large number of genes from 
this list present in our data, as expected (Figures 27, 28, 29, 30).  Interestingly, the 5-aza-
induced senescence produced a senescence-associated secretory phenotype that was more 
robust according to cluster analysis of gene expression comparing senescent cells to 
immortal cells.  The 5-aza sample showed both an increased number of genes from the 
known set as well as increased levels of expression of genes compared to the other 
senescent samples.  This wasn’t necessarily surprising, given that the 5-aza-induced 
senescence sample showed the most robust fold changes in gene expression as well 
compared to other types of senescence when normalized to immortal cells.  The 5-aza-
94 
 
 
 
induced senescence also exhibited a greater number of genes that were differentially 
expressed compared to immortalization than the other types of senescence.  When the 
senescence-associated secretory phenotype genes were analyzed using clustering software, 
the 5-aza-induced senescence associated most closely with natural senescence (Figures 27, 
28, 29, 30). 
This is consistent with the fact that 5-aza works through DNA demethylation and 
natural senescence is due, at least in part, by a natural and progressive demethylation of 
DNA as the cell ages [85].  When the 48 genes differentially expressed in all types of 
senescence were clustered, 5-aza-induced senescence clustered closely to natural 
senescence as well.  It is also important to note that 5-aza- induced senescence reverses 
immortalization; genes that are up-regulated during 5-aza-induced senescence are 
generally silenced during immortalization and the interferon/inflammatory pathway is a 
good example of this.  This is consistent with a recent study showing that 5-aza-induced 
senescence of chronic myeloid leukemia was a result of shortened telomeres, which is the  
mechanism by which natural, replicative senescence occurs [88].  This reinforces the 
concept that replicative senescence is mechanistically similar to 5-aza-induced senescence, 
and that 5-aza-induced senescence is the epigenetic reciprocal of immortalization and 
associated with stabilized telomeres.  Previous studies have shown that cells can have 
telomere attrition and senescence in response to oncogenes [89], and this may contribute 
to tumor suppression.  However, when hTERT is expressed in human cell lines in order to 
stabilize telomeres, the cell will still undergo induced senescence in response to irradiation 
or H2O2, independent of telomere length [90].  Consistently, MDAH041 immortal cells 
used in our study, which utilize telomerase to stabilize telomeres, were still able to undergo 
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senescence in response to H2O2 and adriamycin.  This suggests that although replicative 
senescence and 5-aza-induced senescence may both involve telomere attrition, and 
adriamycin-induced and H2O2-induced do not involve telomere attrition, there is still a 
common pathway between all 4 types of senescence: the interferon pathway.  This study 
provides evidence that although the mechanisms of each type of senescence are different, 
they involve common pathways. 
The adriamycin-induced senescence provided the most intense and consistent 
senescence-associated -galactosidase staining.  However, the gene expression changes 
generally were not as robust as the 5-aza-induced senescence in terms of fold change.  
Additionally, it was interesting that the adriamycin-induced senescence did not have a 
strong senescence-associated secretory phenotype (the adriamycin-induced sample did not 
show high up-regulation of genes present in the SASP, Figure 27), given the strong 
senescence-associated -galactosidase response and consistent with the fact that DNA 
damage is a known contributor to the secretory phenotype [41].  It will be interesting in 
future studies to determine whether the difference in secreted cytokines affects the amount 
of bystander senescence or transformation of surrounding cells. 
4.3 The Role of the IL1 Pathway in Senescence 
Among the several interferon/inflammatory genes that were found to be up-
regulated, several of the genes were present within one pathway: the Interleukin 1 Pathway.  
Il1, Il1, Myd88, ICAM1 and IL8 were all confirmed through RT-PCR analysis to be up-
regulated in the 4 types of senescence compared to immortal cells (Figures 17-23).  It is 
interesting to note that Il1, Il1 and IL8 are all canonical members of the senescence-
associated secretory phenotype, indicating an association between increased gene 
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expression of these members and increased secretion.  Paradoxically, the Interleukin 1 
Receptor Antagonist was also up-regulated in all 4 types of senescence.  However, the 
antagonist serves to inhibit binding of Il1 and Il1 to the Il1 receptor, and Il1/Il1 have 
been shown to exhibit increased activity during senescence, so it is unlikely that the 
receptor antagonist is causing inhibition of the IL1 pathway [68].  
The up-regulation of IL1 family members has been previously shown in various 
cell lines and senescence-inducing drugs.  Bleomycin treatment of the Human sigmoid 
colon adenocarcinoma cell line HCA2 yields an up-regulation of IL1 and Il1 [68].  
Inhibition of IL1 in that study decreased secretion of IL6 and IL8, which are major 
components of the SASP.  Several cancer cell lines such as Hela, A549 and U2OS show 
up-regulated IL1 pathway members in response to 5-bromo-2’-deoxyuridine, distamycin, 
aphidicolin and hydroxyurea which all induce senescence [60].  BJ fibroblasts were shown 
to up-regulate IL1 during replicative senescence, oncogene-induced senescence and 
distamycin-induced senescence [69].  Conditioned media from those senescent cells was 
capable of inducing bystander senescence in BJ fibroblasts, and those cells also exhibited 
up-regulated IL1 expression.  IMR90 cells have up-regulated IL1 pathway members, and 
knockdown of the IL1R which prevents binding of IL1 and Il1 causes a decrease in 
associated paracrine senescence [70].  Therefore, the up-regulation of IL1 pathway 
members that was observed in our RNA-seq data is consistent with other studies, but 
provides a better comparison of multiple types of senescence, as well as immortalization, 
within a single genetic background. 
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4.4 Quiescent Gene Expression  
For the analysis of gene expression data, we included RNA from quiescent cells, in 
order to identify the portion of genes that were not senescence-specific but rather cell cycle 
specific, given that quiescent cells have withdrawn from the cell cycle albeit not 
permanently.  I observed up-regulated 45 genes in all 4 types of senescence and quiescence, 
and therefore these 45 genes were not used for pathway analysis of senescence.  Clustering 
analysis of these 45 genes showed that while the quiescent gene expression had significant 
overlap with the senescent gene expression, the quiescent sample associated very closely 
with the immortal proliferating sample in gene clustering analysis, possibly indicating the 
quiescent-associated genes in the quiescent sample were not as similar to senescent 
samples as they appear based only on fold change analysis.  This further validated our 
reasoning for segregating these genes from the pathway analysis of senescence (Figure 9).  
Surprisingly, pathway analysis on the 45 genes showed interferon/inflammatory pathway 
as the most significant pathway (data not shown).  Among these genes, there were several 
interferon induced proteins, including IFIT1, IFIT2, IFIT3, IFITM1, IFI44L, IFIH1, and 
IFI6.  Additionally, IRF9, an interferon regulatory factor, was also up-regulated in the 
quiescent control, indicating a role for the IRFs in activating the interferon/inflammatory 
pathway in both senescence and quiescence.  IRF3, IRF5 and IRF7 were found in the RNA-
seq data to be up-regulated in senescence but were not consistent among the different types 
of senescence (Figures 5, 6, 7, 16).   
The cell cycle kinase inhibitor p21, which promotes cell cycle arrest, was also up-
regulated in the quiescent control compared to the immortal cells in the Cufflinks analysis 
of differential expression.  However, when relative abundances of quiescent cell gene 
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expression were compared to the 4 types of senescent cells via gene clustering, p21 
appeared slightly down-regulated compared to the senescent samples.  Up-regulation of 
p21 would not be surprising given the fact that the quiescent samples are withdrawn from 
the cell cycle, and therefore p21 may be playing a role in cell cycle arrest.  However, the 
fact that the quiescent sample showed up-regulation in the fold change analysis but down-
regulation of p21 in clustering analysis indicates that the expression of p21 is not as robust 
in the quiescent samples as the senescent samples which are permanently withdrawn from 
the cell cycle. 
4.5 Progressive Up-Regulation of Genes during Cellular Aging 
 In addition to comparing various types of senescence to elucidate common senescent 
pathways, we also wanted to analyze the progression of young, proliferating cells into naturally 
senescent cells.  For this reason, we included lowest available passage cells (PD 10-12), low 
passage cells (PD 17-19), and naturally senescent cells (PD 28-30).  Clustering analysis of the 48 
senescence-associated genes revealed a relative down-regulation of these genes in the lowest 
passage sample, and a slight up-regulation of these genes in the low passage sample.  This is likely 
to represent a property of cells proliferating at a slower rate and approaching senescence.  When 
the cells stopped proliferating and entered natural senescence, the 48 genes were highly up-
regulated.  This illustrates an interesting progressive up-regulation of senescence-associated genes 
which is consistent with the theory that senescence genes are dominant and therefore up-regulated 
during senescence [91].  These senescence-associated genes were predominantly part of the 
inflammatory pathway indicating that the inflammatory/immune response increases as a cell ages 
and this response is silenced during immortalization.  A recent RNA expression study utilized 
young, middle aged, old aged, and naturally senescent IMR90 cells to assess the progression of 
senescence-associated genes.  A progressive down-regulation of 1149 genes was observed, which 
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corresponded to proliferation and replication pathways [11].  There was also a progressive up-
regulation of 454 genes, including the senescence-associated p21 and p16; however pathway 
analysis of these 454 genes did not yield consistent pathway involvement.  These data are consistent 
with our RNA-seq study, showing that several genes become increasingly up-regulated as a cell 
ages, concurrent with the cell proliferation decreasing with age and consequently showing a 
decrease in replication-related genes.  The progressive up-regulation and down-regulation of genes 
is most likely due to the progressive loss of telomeres as a cell ages, as expression of hTERT in the 
IMR90 cells reverted most of the gene expression changes that occurred with senescence [11].   
 As mentioned previously, senescence-associated genes (which are predominantly 
inflammatory/immune system related) are progressively up-regulated during aging and into 
senescence, and this up-regulation is universal throughout all 4 types of senescence.  Inversely, the 
inflammatory/immune system pathway is epigenetically abrogated during cellular immortalization.  
The up-regulation of the inflammatory pathway is most likely due to the expression of the 
senescence-associated secretory phenotype, whereas the silencing of this pathway during 
immortalization seems paradoxical.  It is unclear why it would be advantageous for an immortal 
cell to turn off a protective mechanism such as the innate immune system response.  It is possible 
that the cells with a defective interferon response/immune system pathway have a higher miRNA 
tolerance [59].  Previous studies in the Tainsky lab showed that immortal cells with a dysfunctional 
interferon response (MDAH087-10) had increased levels of miRNAs in response to DICER 
expression, whereas immortal cells with a functional interferon response (MDAH087-N) had 
decreased levels of miRNAs in response to DICER expression.  miRNAs typically serve as negative 
regulators of gene expression, and therefore cells without a functional interferon response and 
consequently higher levels of miRNAs would have high levels of gene repression.  This could cause 
repression of senescence-associated genes or cell cycle inhibitory genes that would hinder the 
growth of a cell, and therefore represent an advantage of having an abrogated interferon response.  
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Similarly, knockdown of DICER in endometrial cancer cell lines causes increased growth and 
migration, concurrent with decrease in miRNA levels [92].  In conjunction with lower total levels 
of miRNA expression, there was an overall increase in interferon-stimulated genes, which is 
consistent with the Tainsky study [92].  This suggests that silencing of the interferon pathway 
during immortalization confers a higher miRNA tolerance than cells with a normal interferon 
response. 
4.6 Senescence as an Approach to Cancer Therapy 
Cancer cells have bypassed the senescent response in order to achieve unrestricted 
growth.  Therefore, re-activation of the senescent response is a logical approach to cancer 
treatment.  However, the ability to exploit senescence during cancer treatment will be 
complicated and require a deeper understanding of the pathways involved.  For instance, it 
may be possible to inhibit senescence in an effort to increase the amount of apoptotic cell 
death during cancer treatment, such as treatment with adriamycin.  It has been shown that 
there are a portion of tumor cells that undergo senescence and not apoptosis in response to 
chemotherapeutic agents [52], and this could be one reason for tumor dormancy.  
“Irreversibly” senescent cells may be a misnomer and these cells may be able to re-enter 
the cell cycle if additional mutations or changes in gene expression are acquired.  
Preliminary experiments have shown that cells treated with H2O2 undergo senescence, but 
are able to begin proliferating again after a short cell cycle arrest (data not shown).  In 
contrast, cells that were treated with adriamycin entered senescence and slowly began 
dying, presumably going through apoptosis but were not able to start proliferating again 
(data not shown).  Therefore, senescence may not be as irreversible as it seems.  RNA-seq 
data from this study showed that in genes differentially expressed in adriamycin-induced 
senescence compared to immortalization, 150 of these genes could be grouped into the 
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apoptosis pathway gene set as defined by Genomatix Genome Analyzer (150 out of 1314 
known apoptosis genes, with a p-value of 4.24-6), indicating that the cell may have the 
option of apoptosis or senescence.  H2O2-induced senescence had 32 out of 1314 known 
apoptosis genes, with a p-value of 2.72-5, again indicating induced senescence can be an 
alternative to apoptosis depending on the circumstance. 
Conversely, it may be beneficial to favor senescence as an outcome for 
chemotherapy rather than try to inhibit it, assuming that senescence is truly “irreversible”.  
However, the senescence-associated secretory phenotype will need to be considered in this 
complex situation because the secreted factors can have a complicated impact on 
surrounding cells, both promoting bystander senescence of normal cells and bystander 
transformation of pre-malignant cells, as well as potentially increasing the overall level of 
inflammation.  Perhaps favoring senescence as an outcome will be beneficial if the 
senescence-associated secretory phenotype is inhibited simultaneously in an effort to 
decrease the effects of the secreted factors.  For example, it has been shown that inhibition 
of IL1 can decrease the levels of factors that are secreted as a result of senescence [68].  
It may also be possible to induce senescence as a cancer therapy, and concurrently stimulate 
the immune system to clear the senescent cells before they are able to secrete inflammatory 
factors that may be detrimental to the surrounding microenvironment by causing bystander 
senescence or bystander transformation. 
4.7 Summary 
Comparison of 4 types of cellular senescence showed a common involvement of 
the inflammatory/immune system pathway during senescence.  Further analysis showed 
heterogeneous involvement of certain inflammatory genes, such as IRF5 and IRF7, 
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indicating that while certain pathways are universal during senescence, the genes involved 
from those pathways can vary among different types of senescence.  I specifically 
confirmed the up-regulation of the IL1 pathway in all types of senescence, and in multiple 
cell lines.  It is probable that this pathway plays a causative role in the senescence-
associated secretory phenotype, which was also present in all 4 types of senescence, though 
to varying degrees.  This RNA-seq study utilized a cell model which allowed a comparison 
between multiple types of senescence within the same genetic background, and 
demonstrated a universal role for the inflammatory pathway in multiple types of 
senescence, as well as a progressive up-regulation of senescence-associated inflammatory 
genes as a cell ages.    
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ABSTRACT 
PATHWAY PROFILING OF REPLICATIVE AND INDUCED SENESCENCE 
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Senescence is a permanent withdrawal from cell cycle that occurs naturally in cells 
in response to the shortening of telomeres.  This natural “clock” serves to limit the number 
of cell divisions and therefore protects the cell from potentially carcinogenic mutations.  
However, senescence also occurs in response to external stresses to the cell, which is 
known as induced senescence.  This study compares the mechanisms of natural senescence, 
a response to the shortening of telomeres during replication, with induced senescence by 
using various drugs to induce senescence: 5-aza-2-deoxycytidine (a demethylating agent), 
Adriamycin (a chemotherapeutic drug), and H2O2 (an agent causing oxidative stress). 
MDAH041 cells, which are fibroblasts isolated from a patient with Li Fraumeni 
Syndrome, have heterozygous alleles of p53 and can therefore undergo natural senescence 
with serial cell culture or at a low frequency spontaneously immortalize once the wildtype 
copy of p53 is lost.  Therefore, this cell model provides naturally senescent cells as well as 
immortal cells which can be treated with the aforementioned drugs resulting in induced 
senescence.  Using these conditions, gene expression profiling was performed.  Gene 
expression analysis revealed 48 genes differentially expressed in all 4 senescence types 
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compared to the immortal control.  Pathway analysis of these 48 genes from all types of 
cellular senescence revealed several pathways, each of which are involved in innate 
immunity, showing for the first time a common gene expression profile among different 
types of senescence, as well as a central role for the IFN pathway in both natural and 
induced senescence.  Specifically, I have focused on the IL1 pathway which is up-regulated 
in all types of senescence compared to immortal proliferating cells and will be the basis for 
additional mechanistic studies.  
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